

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problems Mailbox.**

Set	Items	Description
S1	741914	TRACK? OR TRACE? OR TRACING OR MONITOR? OR LOG? ? OR LOGGI- NG OR AUDIT?
S2	440135	STUDIES OR STUDY OR RESEARCH? OR TRIAL? OR TEST? ?
S3	580221	SAMPLE? OR EXHIBIT? OR BLOOD? OR SERUM
S4	31229	SCIENTIST? OR RESEARCHER? OR WORKER OR ATTENDANT?
S5	4523	S2(2N) (CLINICAL OR MEDICAL?)
S6	412	S1(10N)S5
S7	294	S6 AND S3
S8	0	S7 AND S4
S9	115	S7 AND (PROTOCOL? OR PROCEDUR? OR STEPS)
S10	2	S9 AND IC=G06F?
S11	19	S6 AND IC=G06F?

? show file

File 344:Chinese Patents Abs Aug 1985-2003/Jan

(c) 2003 European Patent Office

File 347:JAPIO Oct 1976-2002/Dec(Updated 030402)

(c) 2003 JPO & JAPIO

File 350:Derwent WPIX 1963-2003/UD,UM &UP=200325

(c) 2003 Thomson Derwent

File 371:French Patents 1961-2002/BOPI 200209

(c) 2002 INPI. All rts. reserv.

11/5/1 (Item 1 from file: 347)  
DIALOG(R)File 347:JAPIO  
(c) 2003 JPO & JAPIO. All rts. reserv.

07419345 \*\*Image available\*\*  
HORIZONTALLY PARALLEL TYPE PERSONAL COMPUTER

PUB. NO.: 2002-287855 [JP 2002287855 A]  
PUBLISHED: October 04, 2002 (20021004)  
INVENTOR(s): KATAHIRA KIMIO  
APPLICANT(s): KATAHIRA KIMIO  
APPL. NO.: 2001-126703 [JP 20011126703]  
FILED: March 22, 2001 (20010322)  
INTL CLASS: G06F-001/16 ; G06F-003/02 ; G09F-009/00; H05K-005/02

#### ABSTRACT

PROBLEM TO BE SOLVED: To improve device structure in which a cause is traced by a medical test made in view of the increase of users complaining of bad physical conditions such as eyestrain, headache and the stiffness and ache of the neck and shoulder, and mental stress following the rapid increase of personal computer users in the spread of the Internet and IT.

SOLUTION: The position relation between a keyboard and a display is changed from the three-dimensional vertical relation into the plane parallel relation. Furthermore, in order to reduce the lateral moving width of a visual axis and to heighten the operating efficiency of both hands, the keyboard is divided and arranged on the right and left sides of the display, close to the right and left hands, to improve the structure. The user's body bends slightly forward in the state of sitting on a chair and placing the hands lightly on a desk so as to be natural with a gentle curve formed from the head to the neck and further to the back. At this time, the visual axis extends obliquely downward to the front at the same angle as the head. This personal computer realizes the structure gentle to the user's body.

COPYRIGHT: (C)2002,JPO

11/5/2 (Item 1 from file: 350)  
DIALOG(R)File 350:Derwent WPIX  
(c) 2003 Thomson Derwent. All rts. reserv.

015186149 \*\*Image available\*\*  
WPI Acc No: 2003-246680/200324

**Sales management and compound interest incentive system - executes data inquiry and update, commission calculation and personnel promotion management**

Patent Assignee: JONNICK CORP (JONN-N)

Inventor: SHING F

Number of Countries: 001 Number of Patents: 001

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
TW 485297	A	20020501	TW 2000120723	A	20001005	200324 B

Priority Applications (No Type Date): TW 2000120723 A 20001005

Patent Details:

Patent No	Kind	Lan Pg	Main IPC	Filing Notes
TW 485297	A		G06F-017/60	

Abstract (Basic): US 20020166133 A1

NOVELTY - An isolated NEOKINE nucleic acid molecule (I) comprising a sequence of 1656, 300, 1372, 237, 1458 or 285 bp given in the specification (designated S1-S6, respectively) or their complements, is new.

DETAILED DESCRIPTION - (I) further comprises:

- (a) a fragment of at least 100 contiguous nucleotides of a sequence selected from S1-S6, or their complements;
- (b) a sequence encoding a polypeptide having a sequence of 99 (P1), 78 (P2) or 94 (P3) amino acids given in the specification;
- (c) a fragment comprising at least 15 contiguous amino acid residues of P1, P2 or P3;
- (d) a naturally occurring allelic variant of P1, P2 or P3, where the nucleic acid molecule hybridizes to a sequence selected from S1-S6 under stringent conditions.

INDEPENDENT CLAIMS are also included for:

- (1) a host cell which contains (I);
- (2) a non-human mammalian host cell containing (I);
- (3) an isolated polypeptide (II) selected from:
  - (a) a fragment comprising at least 15 contiguous amino acids of P1, P2 or P3;
  - (b) a naturally occurring allelic variant of P1, P2 or P3 is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule selected from S1-S6 under stringent conditions;
  - (c) a polypeptide encoded by S1-S6; and
  - (d) a polypeptide comprising P1, P2 or P3;
- (4) an antibody which selectively binds to the polypeptide;
- (5) producing the polypeptide;
- (6) detecting the presence of the polypeptide in a sample;
- (7) detecting the presence of a nucleic acid encoding the polypeptide in a sample;
- (8) a kit comprising a compound which selectively binds to a polypeptide or a compound which selectively hybridizes to (I), and instructions for use;
- (9) identifying a compound which modulates the activity of NEOKINE receptor;
- (10) identifying a compound which modulates binding of NEOKINE to NEOKINE receptor; and
- (11) modulating the activity of a polypeptide by contacting the polypeptide or a cell expressing the polypeptide with a compound which binds to the polypeptide to modulate the activity of the polypeptide.

ACTIVITY - Cytostatic; Antiinflammatory; Antipsoriatic; Immunosuppressive. No clinical data given.

MECHANISM OF ACTION - NEOKINE modulator.

USE - The NEOKINE molecules are useful as modulating agents in regulating a variety of cellular processes, as primers or hybridization probes for the detection of NEOKINE-encoding nucleic acids, in screening assays, in predictive medicine (e.g. diagnostic assays, prognostic assays, **monitoring clinical trials**, and pharmacogenetics), and in method of treatment (therapeutic or prophylactic). The nucleic acids are useful in chromosome mapping, tissue typing, and in forensic biology. The proteins can be used to treat disorders characterized by insufficient or excessive production of non-NEOKINE chemokine or chemokine forms which have decreased or aberrant activity compared to wild type chemokines, and to screen drugs or compounds which modulate NEOKINE activity. NEOKINE modulators are useful for treating and/or preventing proliferative diseases such as cancers of the epithelia, liver, secretory glands, bladder, reproductive tract, central nervous system, or connective tissues, inflammation, psoriasis, or immune rejection following skin graft or kidney transplant.

pp; 64 DwgNo 0/8

Title Terms: SALE; MANAGEMENT; COMPOUND; INTEREST; SYSTEM; EXECUTE; DATA;  
ENQUIRY; UPDATE; COMMISSION; CALCULATE; PERSONNEL; PROMOTE; MANAGEMENT  
Derwent Class: T01  
International Patent Class (Main): G06F-017/60  
File Segment: EPI

11/5/3 (Item 2 from file: 350)  
DIALOG(R)File 350:Derwent WPIX  
(c) 2003 Thomson Derwent. All rts. reserv.

015123549 \*\*Image available\*\*  
WPI Acc No: 2003-184072/200318  
XRPX Acc No: N03-144923

Automatically tracking compliance in clinical trials process by  
associating identifier having unique signature data item with container  
and making database entries

Patent Assignee: GLAXO GROUP LTD (GLAX ); SMITHKLINE BEECHAM PLC (SMIK )  
Inventor: CARTER P L; DAY S; EVANS P G; GEORGE L J  
Number of Countries: 100 Number of Patents: 001  
Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
WO 200301429	A2	20030103	WO 2002EP6895	A	20020621	200318 B

Priority Applications (No Type Date): GB 200115414 A 20010623

Patent Details:

Patent No	Kind	Lan Pg	Main IPC	Filing Notes
WO 200301429	A2	E	34 G06F-019/00	

Designated States (National): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA  
CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN  
IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ  
OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU  
ZA ZM ZW

Designated States (Regional): AT BE CH CY DE DK EA ES FI FR GB GH GM GR  
IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZM ZW

Abstract (Basic): WO 200301429 A2

NOVELTY - Method consists in associating a unique signature ID with  
a container, reading the signature into a database, checking  
performance of an operation relating to the container against a  
compliance standard, and writing the compliance to the database each  
time to check that the correct type or quantity of drug or placebo has  
been used, the cap is in place, the correct container is in the right  
place, suitable environmental conditions have been followed, the  
correct container has been enclosed in the correct secondary pack, the  
correct label has been applied, the container has arrived at the right  
address and the correct information has been received by the recipient.

USE - Method is for automatically tracking compliance in a  
clinical trials process.

ADVANTAGE - Method enables tracking of drug containers to produce  
an audit trail, and ensures that the containers are correctly labelled.

DESCRIPTION OF DRAWING(S) - The figure shows a drug container with  
an RF ID tag.

pp; 34 DwgNo 1a/6

Title Terms: AUTOMATIC; TRACK; COMPLIANT; CLINICAL; PROCESS; ASSOCIATE;  
IDENTIFY; UNIQUE; SIGNATURE; DATA; ITEM; CONTAINER; DATABASE; ENTER  
Derwent Class: S05; T01  
International Patent Class (Main): G06F-019/00  
File Segment: EPI

11/5/4 (Item 3 from file: 350)  
DIALOG(R)File 350:Derwent WPIX  
(c) 2003 Thomson Derwent. All rts. reserv.

015030844 \*\*Image available\*\*  
WPI Acc No: 2003-091361/200308  
XRPX Acc No: N03-072296

Human behavior prediction method in clinical trials, involves generating  
predictive algorithm for predicting human behavior, which is translated  
into prediction rule for use with clinical trial  
Patent Assignee: HUFFORD M R (HUFF-I); PATY J A (PATY-I); SHIFFMAN S  
(SHIF-I)

Inventor: HUFFORD M R; PATY J A; SHIFFMAN S  
Number of Countries: 001 Number of Patents: 001  
Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
US 20020143577	A1	20021003	US 2001825534	A	20010402	200308 B

Priority Applications (No Type Date): US 2001825534 A 20010402  
Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
US 20020143577	A1	11	G06F-017/60		

Abstract (Basic): US 20020143577 A1

NOVELTY - A predictive algorithm for predicting the human behavior  
with respect to a clinical trial is generated. The predictive algorithm  
is translated into prediction rule for use with a clinical trial.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the  
following:

- (1) Human behavior determination method;
- (2) Human behavior abnormality detection method;
- (3) Recorded medium storing instructions for predicting human  
behavior.

USE - For predicting human behavior during clinical trials.

ADVANTAGE - The human behavior during a **clinical trial** is  
predicted and **tracked** reliably with increased statistical power,  
reduced **clinical trial** costs and reduced clinical trial time.

DESCRIPTION OF DRAWING(S) - The figure shows the flowchart of the  
human behavior prediction method.

pp; 11 DwgNo 2/2

Title Terms: HUMAN; BEHAVE; PREDICT; METHOD; CLINICAL; GENERATE; PREDICT;  
ALGORITHM; PREDICT; HUMAN; BEHAVE; TRANSLATION; PREDICT; RULE; CLINICAL;  
TRIAL

Derwent Class: S05; T01

International Patent Class (Main): G06F-017/60

File Segment: EPI

11/5/5 (Item 4 from file: 350)  
DIALOG(R)File 350:Derwent WPIX  
(c) 2003 Thomson Derwent. All rts. reserv.

015014585 \*\*Image available\*\*  
WPI Acc No: 2003-075102/200307  
XRPX Acc No: N03-058142

Research protocol development method for clinical trial, involves  
determining desirability of retaining participant in clinical trial by  
using evaluation data determined from data categories pertaining to  
participant

Patent Assignee: HUFFORD M R (HUFF-I); PATY J A (PATY-I); PETERSON D (PETE-I); SHIFFMAN S (SHIF-I)

Inventor: HUFFORD M R; PATY J A; PETERSON D; SHIFFMAN S

Number of Countries: 001 Number of Patents: 001

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
US 20020143563	A1	20021003	US 2001825533	A	20010402	200307 B

Priority Applications (No Type Date): US 2001825533 A 20010402

Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
US 20020143563	A1		18	G06F-017/60	

Abstract (Basic): US 20020143563 A1

NOVELTY - A clinical trial target is identified and the evaluation data categories pertaining to a participant in the identified clinical trial target is determined. Evaluation data from the data categories is used to determine the desirability of retaining the participant in trial or incorporating the participant in the trial result.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following:

- (1) Preferred targets determination method;
- (2) Subject compliance monitoring method;
- (3) Subject compliance determination method;
- (4) Subject non-compliance prediction method;
- (5) Subject compliance enhancing method;
- (6) Subject compliance monitoring device;
- (7) Clinical trial conduction method; and
- (8) Storage medium storing clinical trial protocol development program.

USE - For developing research protocols used for clinical trials in medical application.

ADVANTAGE - **Tracks** and enhances the subject compliance in the **clinical trial**. Provides reliable valid data, increases statistical power, reduces clinical trial cost, reduces time to complete the clinical trial and reduce the time to get a drug or medical device to market.

DESCRIPTION OF DRAWING(S) - The figure shows the clinical trial conducting system.

pp; 18 DwgNo 1/5

Title Terms: RESEARCH; PROTOCOL; DEVELOP; METHOD; CLINICAL; TRIAL; DETERMINE; RETAIN; PARTICIPATING; CLINICAL; TRIAL; EVALUATE; DATA; DETERMINE; DATA; CATEGORY; PERTAIN; PARTICIPATING

Derwent Class: S05; T01

International Patent Class (Main): G06F-017/60

File Segment: EPI

11/5/6 (Item 5 from file: 350)

DIALOG(R) File 350:Derwent WPIX

(c) 2003 Thomson Derwent. All rts. reserv.

014929753

WPI Acc No: 2002-750462/200281

XRAM Acc No: C02-212643

XRPX Acc No: N02-591053

**New mGluR5M nucleic acid molecules and proteins, useful for treating neurological or psychiatric disorders such as schizophrenia, schizoaffective disorder, bipolar or unipolar affective disorder, or adolescent conduct disorder**

Patent Assignee: GENETICS INST INC (GEMY ); WYETH (AMHP )

Inventor: BATES B G; GULUKOTA K; PAULSEN J E; XIE Y

Number of Countries: 100 Number of Patents: 002

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
WO 200270708	A2	20020912	WO 2001US49817	A	20011221	200281 B
US 20020142330	A1	20021003	US 2000257589	A	20001222	200281
			US 200127923	A	20011221	

Priority Applications (No Type Date): US 2000257589 P 20001222; US 200127923 A 20011221

Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
-----------	------	-----	----	----------	--------------

WO 200270708	A2	E	99	C12N-015/12	
--------------	----	---	----	-------------	--

Designated States (National): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

Designated States (Regional): AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZM ZW

US 20020142330	A1			C12Q-001/68	Provisional application US 2000257589
----------------	----	--	--	-------------	---------------------------------------

Abstract (Basic): WO 200270708 A2

NOVELTY - An isolated metabotropic glutamate receptor subtype 5 modulatory (mGluR5M) nucleic acid molecule (I), is new.

DETAILED DESCRIPTION - An isolated metabotropic glutamate receptor subtype 5 modulatory (mGluR5M) nucleic acid molecule (I), comprising:

(a) a nucleotide sequence that is at least 80% identical to a sequence of 1110 bp (S1), fully defined in the specification, which encodes a polypeptide (II) comprising an N-terminal mGluR-like domain and a C-terminal unique domain;

(b) a nucleic acid molecule that encodes a polypeptide having at least 80% sequence identity to a fully defined sequence of 369 amino acids (P1), given in the specification; and comprising an N-terminal mGluR-like and a C-terminal unique domain, or lacking a transmembrane domain;

(c) a nucleic acid molecule that encodes a polypeptide having at least 80% sequence identity to (P1), where the percent identity is determined using a global alignment algorithm;

(d) a nucleic acid molecule that hybridizes to a complement of (S1), under stringent conditions, and encodes (II);

(e) a nucleic acid molecule that hybridizes to a complement of sequence of 1823 bp (S2), fully defined in the specification, and encodes a polypeptide lacking a transmembrane domain;

(f) a nucleic acid molecule comprising the DNA insert of the plasmid deposited in the American Type Culture Collection (ATCC) as Accession Number PTA-2775; or

(g) a nucleic acid molecule comprising (S2), or its complement or encodes (P1).

INDEPENDENT CLAIMS are also included for:

(1) a host cell containing (I);

(2) a non-human mammalian host cell comprising (I);

(3) an isolated polypeptide comprising:

(a) a polypeptide encoded by (Ia), (Id), (Ie), (If), or (Ig);

(b) an amino acid sequence that is at least 80% identical to (P1) and comprises an N-terminal mGluR-like and a C-terminal unique domain, or lacks a transmembrane domain;

(c) an amino acid sequence that is at least 80% sequence identity to (P1), where the percent identity is determined using a global alignment algorithm; or

(d) an amino acid sequence comprising (P1);



- (4) an antibody, which selectively binds to the polypeptide;
- (5) a method for producing a polypeptide encoded by (I) comprising culturing a host cell containing the nucleic acid molecule, under conditions to express the nucleic acid molecule;
- (6) a method for detecting the presence of the polypeptide or (I);
- (7) kits comprising a compound, which selectively binds to the polypeptide or hybridizes to (I) and instructions for use;
- (8) a method for identifying a compound, which modulates mGluR activity in a cell;
- (9) methods for modulating the activity of mGluR, or neuronal cell signaling; and
- (10) a method for treating a subject having a neurological or psychiatric disorder comprising administering the polypeptide, or its modulator, to treat the disorder.

ACTIVITY - Nootropic; Neuroprotective; Neuroleptic.

No biological data given.

MECHANISM OF ACTION - Gene therapy.

USE - The nucleic acid molecules, polypeptides and antibodies are useful for treating neurological or psychiatric disorders such as schizophrenia, schizoaffective disorder, bipolar affective disorder, unipolar affective disorder or adolescent conduct disorder (claimed).

They are also useful for screening assays, and in predictive medicine (e.g. diagnostic assay, prognostic assays, **monitoring clinical trials**, and pharmacogenetics). The diagnostic assays include chromosome mapping and tissue typing.

pp; 99 DwgNo 0/2

Title Terms: NEW; NUCLEIC; ACID; MOLECULAR; PROTEIN; USEFUL; TREAT; NEUROLOGICAL; PSYCHIATRIC; DISORDER; SCHIZOPHRENIA; DISORDER; BIPOLAR; UNIPOLAR; DISORDER; CONDUCTING; DISORDER

Derwent Class: B04; D16; S03

International Patent Class (Main): C12N-015/12; C12Q-001/68

International Patent Class (Additional): A61K-031/7088; A61K-038/17;

A61K-039/395; C07H-021/04; C07K-014/705; C07K-016/18; C12N-005/06;

C12N-005/10; C12P-021/02; G01N-033/50; G01N-033/53; **G06F-019/00**

File Segment: CPI; EPI

11/5/7 (Item 6 from file: 350)

DIALOG(R)File 350:Derwent WPIX

(c) 2003 Thomson Derwent. All rts. reserv.

014786774 \*\*Image available\*\*

WPI Acc No: 2002-607480/200265

XRPX Acc No: N02-481061

**Remote patient monitoring method for hospital, involves reminding patient of diagnosing or treatment, if server fails to receive confirmation after determined time for diagnosing treatment**

Patent Assignee: TRUSTMED.COM CORP (TRUS-N)

Inventor: CHENG H

Number of Countries: 001 Number of Patents: 001

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
US 20020077851	A1	20020620	US 2001782000	A	20010214	200265 B

Priority Applications (No Type Date): TW 2000122931 A 20001031

Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
US 20020077851	A1	15		G06F-017/60	

Abstract (Basic): US 20020077851 A1

NOVELTY - The diagnosing/treatment time for a patient is determined

according to the patient medical criteria recorded in a patient's medical database and notified to the patient in advance of determined time. The patient is reminded of the diagnosis/treatment, if the network server fails to receive confirmation of his/her diagnosis/treatment after the determined time.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for diagnosing patient watching system.

USE - For monitoring hypertensive patient, diabetic patient, also for **monitoring** child to be vaccinated for use in hospital, **medical research** organization.

ADVANTAGE - By effectively reminding the patient about their appointment, the higher risk of seizure or death is prevented.

DESCRIPTION OF DRAWING(S) - The figure shows the flowchart explaining the diagnosed patient monitoring procedure.

pp; 15 DwgNo 1/6

Title Terms: REMOTE; PATIENT; MONITOR; METHOD; HOSPITAL; PATIENT; DIAGNOSE; TREAT; SERVE; FAIL; RECEIVE; CONFIRM; AFTER; DETERMINE; TIME; DIAGNOSE; TREAT

Derwent Class: S05; T01

International Patent Class (Main): G06F-017/60

File Segment: EPI

11/5/8 (Item 7 from file: 350)

DIALOG(R)File 350:Derwent WPIX

(c) 2003 Thomson Derwent. All rts. reserv.

014402351 \*\*Image available\*\*

WPI Acc No: 2002-223054/200228

**System and method for processing clinical test data thereof**

Patent Assignee: CHOI W J (CHOI-I); YOON S M (YOON-I)

Inventor: CHOI W J; YOON S M

Number of Countries: 001 Number of Patents: 001

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
KR 2001096807	A	20011108	KR 200019714	A	20000414	200228 B

Priority Applications (No Type Date): KR 200019714 A 20000414

Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
KR 2001096807	A		1	G06F-017/40	

Abstract (Basic): KR 2001096807 A

NOVELTY - A system and method for processing clinical test data are provided to enable a clinical test researcher to input case recording data directly through a computer network and enable another person(a **clinical test** client, a **monitor** personnel, an inspector) certified for sharing case recording data to receive and use the information in real time.

DETAILED DESCRIPTION - A user information database(100) stores recognition information of the clinical test interested. A clinical test database(110) stores all sorts of case record, clinical test data inputted in the records, and a clinical plan. An error check server(120) judges whether the clinical test data are correct when the clinical test data are inputted in the case records. A data processing server(160) certifies the clinical test interested, suggests the case records through the terminal, and stores clinical test data in accordance with the case records in the clinical test database(110).

pp; 1 DwgNo 1/10

Title Terms: SYSTEM; METHOD; PROCESS; CLINICAL; TEST; DATA

Derwent Class: T01

International Patent Class (Main): G06F-017/40  
File Segment: EPI

11/5/9 (Item 8 from file: 350)  
DIALOG(R)File 350:Derwent WPIX  
(c) 2003 Thomson Derwent. All rts. reserv.

014359373  
WPI Acc No: 2002-180074/200223  
XRAM Acc No: C02-056026

**New isolated cytoplasmic, nuclear, membrane bound, or secreted polypeptide, useful for treating cardiomyopathy, atherosclerosis, infections, cancer, neurodegenerative, metabolic, hematopoietic and immune disorders**

Patent Assignee: AMERICA ONLINE INC (AMON-N); CURAGEN CORP (CURA-N);  
ALSOBROOK J P (ALSO-I); BURGESS C E (BURG-I); ELLERMAN K (ELLE-I);  
GERLACH V L (GERL-I); GROSSE W M (GROS-I); GUSEV V Y (GUSE-I); LEPLEY D M  
(LEPL-I); LI L (LILL-I); MACDOUGALL J R (MACD-I); PADIGARU M (PADI-I);  
RASTELLI L (RAST-I); SHENOY S G (SHEN-I); SHIMKETS R A (SHIM-I); SMITHSON  
G (SMIT-I); SPADERNA S K (SPAD-I); SPYTEK K A (SPYT-I); STONE D J  
(STON-I); TAUPIER R J (TAUP-I); ZERHUSEN B D (ZERH-I)

Inventor: ALSOBROOK J P; BURGESS C E; ELLERMAN K; GERLACH V L; GROSSE W M;  
GUSEV V Y; LEPLEY D M; LI L; MACDOUGALL J R; PADIGARU M; RASTELLI L;  
SHENOY S G; SHIMKETS R A; SMITHSON G; SPADERNA S K; SPYTEK K A; STONE D J  
; TAUPIER R J; ZERHUSEN B D; BURGESS C; CASMAN S; MEZES P; MISHRA V

Number of Countries: 095 Number of Patents: 004

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
WO 200210216	A2	20020207	WO 2001US24225	A	20010730	200223 B
AU 200183089	A	20020213	AU 200183089	A	20010730	200238
AU 200177008	A	20020218	AU 200177008	A	20010720	200244
US 20030064369	A1	20030403	US 2000221409	P	20000728	200325
			US 2000222840	P	20000804	
			US 2000223752	P	20000804	
			US 2000223762	P	20000804	
			US 2000223769	P	20000804	
			US 2000223770	P	20000804	
			US 2000225146	P	20000814	
			US 2000225392	P	20000815	
			US 2000225470	P	20000815	
			US 2000225697	P	20000816	
			US 2001263662	P	20010201	
			US 2001281645	P	20010405	
			US 2001918779	A	20010730	

Priority Applications (No Type Date): US 2001281645 P 20010405; US  
2000221409 P 20000728; US 2000222840 P 20000804; US 2000223752 P 20000804  
; US 2000223762 P 20000804; US 2000223769 P 20000804; US 2000223770 P  
20000804; US 2000225146 P 20000814; US 2000225392 P 20000815; US  
2000225470 P 20000815; US 2000225697 P 20000816; US 2001263662 P 20010201  
; US 2001860639 A 20010521; US 2001918779 A 20010730

Patent Details:

Patent No Kind Lan Pg Main IPC Filing Notes  
WO 200210216 A2 E 213 C07K-014/705

Designated States (National): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA  
CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS  
JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL  
PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

Designated States (Regional): AT BE CH CY DE DK EA ES FI FR GB GH GM GR  
IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW

AU 200183089 A	C07K-014/705	Based on patent WO 200210216
AU 200177008 A	G06F-017/60	Based on patent WO 200213089
US 20030064369 A1	C12Q-001/68	Provisional application US 2000221409

Provisional application US 2000222840  
Provisional application US 2000223752  
Provisional application US 2000223762  
Provisional application US 2000223769  
Provisional application US 2000223770  
Provisional application US 2000225146  
Provisional application US 2000225392  
Provisional application US 2000225470  
Provisional application US 2000225697  
Provisional application US 2001263662  
Provisional application US 2001281645

Abstract (Basic): WO 200210216 A2

NOVELTY - An isolated cytoplasmic, nuclear, membrane bound, or secreted polypeptide (NOVX) (I) selected from a sequence (S1) of 898, 193, 841, 1086, 664, 717, 46, 606, 380, 365, 1210, or 452 amino acids, given in the specification, a variant of S1, a mature form of S1, and a variant of the mature form of S1, is new.

DETAILED DESCRIPTION - A new isolated cytoplasmic, nuclear, membrane bound, or secreted polypeptide (NOVX) (I) is selected from a sequence (S1) of 898, 193, 841, 1086, 664, 717, 46, 606, 380, 365, 1210, or 452 amino acids, given in the specification, a variant of S1, a mature form of S1, and a variant of the mature form of S1. In (I), one or more amino acids in the variant of S1 or the variant of the mature form of S1, differs from S1 or the mature form of S1, provided that the variant differs in no more than 15 % of the amino acid residues from S1 or the mature form of S1. INDEPENDENT CLAIMS are also included for the following:

- (1) an isolated nucleic acid molecule (II) selected from a sequence encoding (I), or its complement;
- (2) a vector (III) comprising (II);
- (3) a cell (IV) comprising (III);
- (4) an antibody (V) that binds immunospecifically to (I);
- (5) determining (M1) the presence or amount of (I) or (II) in a sample comprising contacting the sample with an antibody that binds (I) or a probe that binds (II);
- (6) modulating (M2) an activity of (I), by contacting a cell sample expressing (I) with a compound that binds to (I);
- (7) a pharmaceutical composition (VI) comprising (I), (II), or (V);
- (8) a kit comprising (VI);
- (9) determining (M3) the presence of or predisposition to a disease associated with altered levels of (I) or (II) in a mammalian subject comprising:
  - (a) measuring the level of expression of (I) or (II) in a first mammalian subject; and
  - (b) comparing the level to the level of (I) or (II) in a control sample from a second mammalian subject known not to have, or not to be predisposed to, the disease; and
- (10) treating (M4) a pathological state in mammal, by administering to the mammal a polypeptide having a sequence at least 95 % identical to the polypeptide comprising S1 or its biological active fragment.

ACTIVITY - Antiatherosclerotic; antidiabetic; nootropic; neuroprotective; anorectic; immunomodulator; cytostatic; antiparkinsonian; antibacterial; fungicide; protozoacide; virucide; analgesic; antiasthmatic; hypotensive; osteopathic; antiinflammatory; neuroprotective; cardiatic; antianginal; antiulcer; antiallergic; tranquilizer; neuroleptic; antidepressant; antilipemic; anticonvulsant.

MECHANISM OF ACTION - Gene therapy; NOVX activity modulator. No biological data is given.

USE - (I), nucleic acid (II) encoding (I) or an antibody (V) that binds (I) is useful for treating or preventing a NOVX-associated disorder, where the disorder is selected from cardiomyopathy, atherosclerosis, diabetes, or a disorder related to cell signal processing and metabolic pathway modulation. (V) is useful for treating a pathological state in a mammal. (I) is useful for identifying an agent that binds to (I), or for identifying an agent that modulates the expression or activity (I). (V) is useful for determining the presence or amount of (I) in a sample (claimed). (I), (II) or (V) is useful for treating metabolic disorders, obesity, infectious disease, anorexia, cancer-associated cachexia, cancer, neurodegenerative disorders, Alzheimer's disease, Parkinson's disorder, immune disorders, hematopoietic disorders, and the various dyslipidemias, metabolic disturbances associated with obesity, the metabolic syndrome X and wasting disorders associated with chronic diseases and various cancers. (I), (II) or (V) is also useful for treating bacterial, fungal, protozoal and viral infections, pain, anorexia, bulimia, asthma, hypertension, urinary retention, osteoporosis, Crohn's disease, multiple sclerosis, Albright Hereditary Osteodystrophy, angina pectoris, myocardial infarction, ulcer, allergy, benign prostatic hypertrophy, and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, and dyskinesias, such as Huntington's disease and Gilles de la Tourette syndrome. (I), (II) or (V) is useful in screening assays, detection assays (e.g., chromosomal mapping, tissue typing, forensic biology), predictive medicine (e.g., diagnostic assays, prognostic assays, **monitoring clinical trials** and pharmacogenomic), and in methods of treatment (e.g., therapeutic and prophylactic). (I) is useful as immunogen to produce antibodies immunospecific for (I), to screen for potential agonist and antagonist compounds, and as bait protein in a two-hybrid or three-hybrid assay. (II) is useful in gene therapy, to express (I), to detect NOVX mRNA or a genetic lesion in a NOVX gene, and to modulate NOVX activity. A cell (IV) comprising (II) is useful for producing non-human transgenic animals. (V) is useful for isolating, and purifying (I) and to monitor protein levels in tissue as part of a clinical testing procedure.

pp; 213 DwgNo 0/0

Title Terms: NEW; ISOLATE; CYTOPLASM; NUCLEAR; MEMBRANE; BOUND; SECRETION; POLYPEPTIDE; USEFUL; TREAT; ATHEROSCLEROSIS; INFECT; CANCER; METABOLISM; HAEMATOPOIETIC; IMMUNE; DISORDER

Derwent Class: B04; D16; T01

International Patent Class (Main): C07K-014/705; C12Q-001/68; **G06F-017/60**

International Patent Class (Additional): C07H-021/04; C07K-014/435;

C12N-005/06; C12N-009/00; C12P-021/02

File Segment: CPI; EPI

11/5/10 (Item 9 from file: 350)

DIALOG(R)File 350:Derwent WPIX

(c) 2003 Thomson Derwent. All rts. reserv.

014314292 \*\*Image available\*\*

WPI Acc No: 2002-134994/200218

XRPX Acc No: N02-102051

**Clinical trial monitoring system, stores test data received from different clinical trial sites in database, based on which monitor center produces final report**

Patent Assignee: MOSU YG (MOSU-N)

Number of Countries: 001 Number of Patents: 001

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
JP 2001312557	A	20011109	JP 2000128523	A	20000427	200218 B

Priority Applications (No Type Date): JP 2000128523 A 20000427

Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
JP 2001312557	A		4	G06F-017/60	

Abstract (Basic): JP 2001312557 A

NOVELTY - The system receives test data obtained by subjecting the patients of several clinical trial sites, to the trial medicine for predetermined duration. The data received from the trial site, are stored in a database. A monitor center monitors the stored data, based on which a final report of trial medicine is output..

USE - **Clinical trial monitoring** system.

ADVANTAGE - The final report of the trial medicines, is produced efficiently and quickly, and the burden of the doctor is reduced.

DESCRIPTION OF DRAWING(S) - The figure shows the **clinical trial monitoring** system. (Drawing includes non-English language text).

pp; 4 DwgNo 1/1

Title Terms: CLINICAL; TRIAL; MONITOR; SYSTEM; STORAGE; TEST; DATA; RECEIVE ; CLINICAL; TRIAL; SITE; DATABASE; BASED; MONITOR; PRODUCE; FINAL; REPORT

Derwent Class: P33; T01

International Patent Class (Main): **G06F-017/60**

International Patent Class (Additional): A61G-012/00

File Segment: EPI; EngPI

11/5/11 (Item 10 from file: 350)

DIALOG(R)File 350:Derwent WPIX

(c) 2003 Thomson Derwent. All rts. reserv.

014262287

WPI Acc No: 2002-082985/200211

XRAM Acc No: C02-025134

**New membrane transport protein and polynucleotides, useful for diagnosing and treating transport protein related disorders e.g. cancer, restenosis, asthma and Alzheimer's disease and to identify modulators of therapeutic use**

Patent Assignee: MILLENNIUM PHARM INC (MILL-N); SPENCER M A (SPEN-I);

CURTIS R A J (CURT-I); GLUCKSMANN M A (GLUC-I)

Inventor: SPENCER M A; CURTIS R A J; GLUCKSMANN M A; GLUCKSMANN M

Number of Countries: 096 Number of Patents: 004

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
WO 200187978	A2	20011122	WO 2001US15533	A	20010514	200211 B
AU 200161572	A	20011126	AU 200161572	A	20010514	200222
US 20020042812	A1	20020411	US 2000204211	P	20000512	200227
			US 20018208	A	20011103	
US 20020061590	A1	20020523	US 2000204211	P	20000512	200239
			US 2001858194	A	20010514	

Priority Applications (No Type Date): US 2000204211 P 20000512; US 20018208 A 20011103; US 2001858194 A 20010514

Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
WO 200187978	A2	E	141	C07K-014/705	

Designated States (National): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA

CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN  
IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ  
PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW  
Designated States (Regional): AT BE CH CY DE DK EA ES FI FR GB GH GM GR  
IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW

AU 200161572 A C07K-014/705 Based on patent WO 200187978  
US 20020042812 A1 G06F-015/173 Provisional application US 2000204211

US 20020061590 A1 C07H-021/02 Provisional application US 2000204211

Abstract (Basic): WO 200187978 A2

NOVELTY - An isolated membrane transporter protein-1 (MTP-1) (I), comprising a sequence 80% identical to a sequence (S1) of 2144 amino acids (aa) given in specification, a fragment of 15 contiguous amino acids of (S1), a naturally occurring allelic variant of (S1) or aa sequence encoded by polynucleotide which hybridizes to a sequence (S2) of 6768 or 6432 base pairs as given in the specification under stringent conditions, is new.

DETAILED DESCRIPTION - An isolated membrane transporter protein-1 (MTP-1) (I) comprising:

(a) a fragment of a polypeptide comprising a fully defined sequence (S1) of 2144 amino acids as given in the specification, where the fragment comprises at least 15 contiguous amino acids;

(b) a naturally occurring allelic variant of S1 encoded by a nucleic acid molecule which hybridizes to a fully defined sequence (S2) of 6768 or 6432 base pairs as given in the specification under stringent conditions;

(c) a polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence at least 80% identical to S2; or

(d) a polypeptide comprising an amino acid sequence at least 80% identical to S1, is new.

INDEPENDENT CLAIMS are also included for the following:

(1) an isolated NA molecule (II) or its complement comprising a nucleotide sequence which is 80% identical to S2, a fragment of 50 nucleotides of S2, a sequence encoding (I) or its fragment of 15 contiguous amino acids;

(2) an isolated polynucleotide (IIb) which hybridizes to (II) under stringent conditions;

(3) an isolated polynucleotide (IIc) comprising a sequence complementary to (II);

(4) a vector (III) comprising (II);

(5) a host cell (IV) transfected with (III);

(6) preparation of (I);

(7) an antibody (Ab) specific to (I);

(8) detecting (M1) the presence of (I) in a sample, by contacting the sample with a compound that binds to (I) and determining whether the compound binds to (I) in the sample;

(9) detecting (M2) the presence of (II) in a sample, by contacting the sample with a nucleic acid probe or primer which selectively binds to (II) and determining whether the probe or primer binds to (II) in the sample;

(10) a kit comprising a compound which selectively binds to (I) or a compound which selectively hybridizes to (II), and instructions for use; and

(11) modulating (M3) the activity of (I), by contacting (I) or cell expressing (I) with a compound which binds to (I) to modulate the activity of (I).

ACTIVITY - Cytostatic; Nootropic; Neuroprotective; Antiparkinsonian; Anticonvulsant; Antianemic; Anorectic; Antidiabetic; Antiarteriosclerotic; Anti-human immunodeficiency virus (HIV); Antiarthritic; Immunosuppressive; Antiasthmatic; Tuberculostatic;

Antiulcer; Neuroprotective; Antimanic; Tranquilizer; Vasotropic; No supporting data is given.

MECHANISM OF ACTION - Gene therapy; Modulator of (I) or (II).

USE - (M1) is useful for detecting the presence of (I) in a sample. (M2) is useful for detecting the presence of (II) in the sample. Both the methods are useful for identifying a subject having a cellular proliferation, growth, apoptosis, differentiation and/or migration disorder, or at risk for developing the disorder, where the probe comprises at least 25 contiguous nucleotides of (S2) and the primers which includes a first primer comprising at least 25 contiguous nucleotides of (S2) and second amplification primer comprising 25 contiguous nucleotides from complement of (S2) (all claimed). (I) is useful for identifying a compound which modulates the activity of (I). The method comprises contacting (I) or cell expressing (I) with a test compound and determining whether (I) bind to the test compound or determining the effect of the compound on the activity or expression of (I), where the binding of the test compound to (I) is determined by detecting binding by direct detection of a test compound/polypeptide binding, detection of binding by using a competition binding assay or an assay for MTP-1 activity (claimed), where the identified compound (modulator) of (I) is useful in treatment and diagnosis of a subject having a disorders characterized by aberrant or unwanted MTP-1 protein or nucleic acid expression or activity, where transporter-associated disorders include hematopoietic disorders (e.g. hematopoietic associated diseases and disorders such as acute myeloid leukemia, hemophilia, leukemia, anemia), leukocytic disorders (e.g. leukopenias, non-Hodgkin's lymphomas), disorders related to lipid metabolism (e.g. obesity, anorexia nervosa, diabetes mellitus, arteriosclerosis, atherosclerosis, atherogenesis), disorders involving abnormal vascularization (e.g. vascularization of solid tumors), immunological disorders (e.g. autoimmune disorders such as arthritis, graft rejection, T cell disorders, immune deficiency disorders), inflammatory diseases or disorders (e.g. asthma, tuberculosis, nephritis, inflammatory bowel disease, ulcers), central nervous system (CNS) disorders (e.g. Alzheimer's disease, dementias related Alzheimer's disease, palsy, epilepsy, mania, anxiety disorders, obsessive-compulsive disorders), cardiac-related disorders (e.g. ischemia reperfusion injury, restenosis, arterial inflammation, vascular wall remodeling, ventricular remodeling, rapid ventricular pacing, coronary microembolism), disorders also include cellular proliferation, growth, differentiation (e.g. carcinoma, sarcoma, or leukemia, hepatic disorders), disorders also include hormonal disorders (e.g. type I and type II diabetes mellitus) and reproductive or fertility disorders. (I), (II) or Ab is used in screening assays, predictive medicine (e.g., diagnostic assays, prognostic assays, **monitoring clinical trials**, and pharmacogenetics) and methods of treatment (e.g. therapeutic and prophylactic). Fragments of (II) are also useful to synthesize antisense molecules of desired length and sequences. (II) is also useful to detect mutations in genes and gene expression products such as mRNA, as antisense constructs to control gene expression and for chromosome identification. (III) is useful for producing proteins and polypeptides, for conducting cell-based assays involving the protein or fragments and to produce non-human transgenic animals which are useful for studying the function of a receptor protein and identifying and evaluating modulators of the protein activity.

pp; 141 DwgNo 0/4

Title Terms: NEW; MEMBRANE; TRANSPORT; PROTEIN; USEFUL; DIAGNOSE; TREAT;  
TRANSPORT; PROTEIN; RELATED; DISORDER; CANCER; ASTHMA; DISEASE; IDENTIFY;  
MODULATE; THERAPEUTIC  
Derwent Class: B04; D16



International Patent Class (Main): C07H-021/02; C07K-014/705; G06F-015/173

International Patent Class (Additional): C07H-021/04; C07K-001/00;

C07K-014/00; C07K-017/00; C12N-015/02

File Segment: CPI

11/5/12 (Item 11 from file: 350)

DIALOG(R) File 350:Derwent WPIX

(c) 2003 Thomson Derwent. All rts. reserv.

014245861 \*\*Image available\*\*

WPI Acc No: 2002-066561/200209

XRPX Acc No: N02-049413

**Apparatus for determining threshold value in nucleic acid amplification reaction for medical applications, calculates derivative data points of growth curve, to determine threshold value**

Patent Assignee: CEPHEID (CEPH-N)

Inventor: BORKHOLDER D A; CHRISTEL L A; MCMILLAN W A; YOUNG S J; LEE C A

Number of Countries: 095 Number of Patents: 006

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
WO 200184463	A2	20011108	WO 2001US13966	A	20010430	200209 B
AU 200159290	A	20011112	AU 200159290	A	20010430	200222
US 20020031768	A1	20020314	US 2000562195	A	20000501	200222
			US 2001808706	A	20010314	
US 20020034745	A1	20020321	US 2000562195	A	20000501	200224
			US 2001808674	A	20010314	
US 20020034746	A1	20020321	US 2000562195	A	20000501	200224
			US 2001808877	A	20010314	
US 20020058282	A1	20020516	US 2000562195	A	20000501	200237
			US 2001808674	A	20010314	
			US 200127404	A	20011219	

Priority Applications (No Type Date): US 2000562195 A 20000501; US

2001808706 A 20010314; US 2001808674 A 20010314; US 2001808877 A 20010314

; US 200127404 A 20011219

Patent Details:

Patent No Kind Lan Pg Main IPC Filing Notes

WO 200184463 A2 E 215 G06F-019/00

Designated States (National): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA  
CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS  
JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL  
PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

Designated States (Regional): AT BE CH CY DE DK EA ES FI FR GB GH GM GR  
IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW

AU 200159290 A G06F-019/00 Based on patent WO 200184463

US 20020031768 A1 C12Q-001/68 Div ex application US 2000562195

US 20020034745 A1 C12Q-001/68 Div ex application US 2000562195

US 20020034746 A1 C12Q-001/68 Div ex application US 2000562195

US 20020058282 A1 C12Q-001/68 Div ex application US 2000562195

Cont of application US 2001808674

Abstract (Basic): WO 200184463 A2

NOVELTY - A controller stores detected signal values defining growth curve for nucleic acid sequence, to obtain derivative data points which are used to fit a curve. A threshold value indicating number of cycles to reach arbitrary fluorescent value and elapsed amplification time, is calculated associated with the peak of the curve.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the

following:

(a) Apparatus for determining concentration of target nucleic acid sequence;

(b) Method for determining threshold value in nucleic acid amplification reaction;

(c) Method for determining target nucleic acid sequence;

(d) Computer program product

USE - Used in biological and **medical research** to monitor the levels of human immuno deficiency virus (HIV).

ADVANTAGE - The concentration of nucleic acid sequence in a test sample is determined efficiently.

DESCRIPTION OF DRAWING(S) - The figure shows a partially exploded isometric view of the reaction vessel used in nucleic acid amplification reaction.

pp; 215 DwgNo 1/54

Title Terms: APPARATUS; DETERMINE; THRESHOLD; VALUE; NUCLEIC; ACID; AMPLIFY ; REACT; MEDICAL; APPLY; CALCULATE; DERIVATIVE; DATA; POINT; GROWTH; CURVE; DETERMINE; THRESHOLD; VALUE

Derwent Class: S03; S05; T01

International Patent Class (Main): C12Q-001/68; **G06F-019/00**

International Patent Class (Additional): C12M-001/34; C12P-019/34;

G01N-033/48; G01N-033/50

File Segment: EPI

**11/5/13 (Item 12 from file: 350)**

DIALOG(R)File 350:Derwent WPIX

(c) 2003 Thomson Derwent. All rts. reserv.

014004312 \*\*Image available\*\*

WPI Acc No: 2001-488526/200153

XRPX Acc No: N01-361499

**Automated computer tracking for biological samples taken during clinical studies , by storing the status and location of samples in a central database**

Patent Assignee: PPGX INC (PPGX-N); MARKIDAN I (MARK-I); MELNICK J H (MELN-I); OBEROI H (OBER-I)

Inventor: MARKIDAN I; MELNICK J H; OBEROI H

Number of Countries: 094 Number of Patents: 003

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
WO 200143038	A1	20010614	WO 2000US33938	A	20001213	200153 B
AU 200121017	A	20010618	AU 200121017	A	20001213	200161
US 20010032060	A1	20011018	US 99170432	A	19991213	200166
			US 2000736619	A	20001213	

Priority Applications (No Type Date): US 99170432 P 19991213; US 2000736619 A 20001213

Patent Details:

Patent No Kind Lan Pg Main IPC Filing Notes

WO 200143038 A1 E 24 G06F-017/60

Designated States (National): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

Designated States (Regional): AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW

AU 200121017 A G06F-017/60 Based on patent WO 200143038

US 20010032060 A1 G06F-011/30 Provisional application US 99170432

Abstract (Basic): WO 200143038 A1

NOVELTY - The automated computerized system integrates the tracking of individual biological samples using bar-code identifiers and computerized scanners with checklists of procedures to be performed on each sample. Information regarding status and location of samples is stored in a central database allowing for the generation of complete location, chain of custody, and test reports.

USE - For biological samples taken during clinical studies.

ADVANTAGE - Provides accurate and efficient computerized tracking that would be extremely difficult to achieve using traditional paper-based systems.

DESCRIPTION OF DRAWING(S) - The figure shows a flow chart of the computerized tracking system for biological samples.

pp; 24 DwgNo 1/11

Title Terms: AUTOMATIC; COMPUTER; TRACK; BIOLOGICAL; SAMPLE; CLINICAL;

STUDY; STORAGE; STATUS; LOCATE; SAMPLE; CENTRAL; DATABASE

Derwent Class: S03; S05; T01

International Patent Class (Main): G06F-011/30 ; G06F-017/60

File Segment: EPI

11/5/14 (Item 13 from file: 350)

DIALOG(R)File 350:Derwent WPIX

(c) 2003 Thomson Derwent. All rts. reserv.

013522903 \*\*Image available\*\*

WPI Acc No: 2001-007109/200101

XRAM Acc No: C01-001760

XRPX Acc No: N01-005104

**Biological marker and phenotype identification system, useful in drug development, using processor to correlate data regarding e.g. cell populations, soluble factor levels and clinical parameters**

Patent Assignee: SURROMED INC (SURR-N)

Inventor: ALLISON A; BRUNKE K J; DIETZ L J; KANTOR A B; NATAN M J; RINGOLD

G

Number of Countries: 090 Number of Patents: 007

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
WO 200065472	A1	20001102	WO 2000US11296	A	20000426	200101 B
AU 200044942	A	20001110	AU 200044942	A	20000426	200109
KR 2002003384	A	20020112	KR 2001713650	A	20011025	200247
EP 1224564	A1	20020724	EP 2000926411	A	20000426	200256
			WO 2000US11296	A	20000426	
BR 200010068	A	20021217	BR 200010068	A	20000426	200309
			WO 2000US11296	A	20000426	
ZA 200108757	A	20021224	ZA 20018757	A	20011024	200309
JP 2002543394	W	20021217	JP 2000614148	A	20000426	200312
			WO 2000US11296	A	20000426	

Priority Applications (No Type Date): US 2000175075 P 20000107; US 99131105 P 19990426

Patent Details:

Patent No Kind Lan Pg Main IPC Filing Notes

WO 200065472 A1 E 104 G06F-017/00

Designated States (National): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

Designated States (Regional): AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SL SZ TZ UG ZW

AU 200044942 A G06F-017/00 Based on patent WO 200065472

KR 2002003384 A G06F-017/00

EP 1224564 A1 E G06F-017/00 Based on patent WO 200065472  
 Designated States (Regional): AL AT BE CH CY DE DK ES FI FR GB GR IE IT  
 LI LT LU LV MC MK NL PT RO SE SI  
 BR 200010068 A G06F-017/00 Based on patent WO 200065472  
 ZA 200108757 A 114 G06F-000/00  
 JP 2002543394 W 119 G01N-033/48 Based on patent WO 200065472

Abstract (Basic): WO 200065472 A1

NOVELTY - A biological marker (BM) identification system comprising an integrated database containing several data categories and data from various organisms corresponding to the data categories, is new.

DETAILED DESCRIPTION - A biological marker (BM) identification system comprises:

(a) an integrated database containing several data categories, i.e. levels of cell populations, cell associated molecules and/or soluble factors in a biological fluid and information associated with clinical parameters of an organism; and

(b) data from various organisms corresponding to the data categories.

A processor correlates data within the categories, to identify the category (or categories) indicating normal biological or pathogenic processes or responses to drug intervention; this category (or these categories) is/are BM.

INDEPENDENT CLAIMS are also included for the following:

(1) a method for identifying a BM for a given disease or medical condition (GD/MC), comprising correlating information associated with several categories (as in (a) above) from several organisms, at least some of which have GD/MC and identifying a data category (i.e. BM) by which the presence of GD/MC can be identified;

(2) a phenotype of an organism comprising several biological parameters, i.e. the results of at least 20 (preferably at least 40) assays relating to cell populations and/or cell associated molecules, the results of at least 20 (preferably at least 40) assays relating to soluble factors and clinical parameters;

(3) a phenotype of a class or subclass of organisms, comprising parameters as in (2) for each member;

(4) a system for creating the phenotype of an organism, involving obtaining parameters as in (2);

(5) a method for evaluating the effect of a perturbation on an organism (or on a class or subclass of organisms), involving comparing the information in the phenotype, as in (2) or (3), of the organism(s) before and after the perturbation;

(6) a system for the identification of BM's of a GD/MC in an animal model, involving an integrated database and processor as above;

(7) a method for identifying a BM for GD/MC in a human, involving determining if a BM in an animal model as in (6) is diagnostic or prognostic of GD/MC in a human;

(8) a method for assaying a candidate drug, involving treating an animal model with the drug and evaluating the effect on a BM as in (6);

(9) a method for **monitoring** the results of a **clinical study** in humans with a GD/MC, involving identifying BM's in a human which are homologs of BM's identified in animal models of GD/MC;

(10) a method for designing an improved animal model for a GD/MC in humans, involving identifying human BM's relative to the GD/MC and tailoring the animal model to simulate GD/MC more accurately by elevating or reducing the levels of animal homologs of the human BM;

(11) a method for identifying an animal model of a GD/MC, involving comparing phenotypes (as in (2)) for potential animal models and an organism having the GD/MC, to identify the most closely simulating animal model phenotype; and

(12) a method for evaluating the effects of a the effects of a

genetic alteration on a plant or animal, involving comparing information on phenotypes (as in (2)) for the genetically altered and non-altered organism to identify changed parameters.

USE - The systems and phenotypes are useful in drug development. The diseases involved are specifically asthma, allergy, multiple sclerosis or especially rheumatoid arthritis (all claimed). More generally the phenotypes may be of humans, animals, plants or viruses (all claimed); they may also be used for evaluating the effects of a genetic alteration on a plant or animal.

ADVANTAGE - The technology is supplied for providing quantitative, sensitive, reproducible and rapid measurements of multiple and diverse BM's which can accurately profile an organism's phenotype or a patient's disease status and response to therapy. More cost-effective drug development is possible. The biological parameters can be identified from small samples of blood.

DESCRIPTION OF DRAWING(S) - The figure is a schematic representation of the types of information assimilated to obtain a biological marker identification system.

pp; 104 DwgNo 1/9

Title Terms: BIOLOGICAL; MARK; PHENOTYPE; IDENTIFY; SYSTEM; USEFUL; DRUG; DEVELOP; PROCESSOR; CORRELATE; DATA; CELL; POPULATION; SOLUBLE; FACTOR; LEVEL; CLINICAL; PARAMETER

Derwent Class: B04; D16; J04; S03; T01

International Patent Class (Main): G01N-033/48; G06F-000/00 ; G06F-017/00

International Patent Class (Additional): G01N-033/483; G01N-033/53; G01N-033/68

File Segment: CPI; EPI

11/5/15 (Item 14 from file: 350)

DIALOG(R) File 350:Derwent WPIX

(c) 2003 Thomson Derwent. All rts. reserv.

012832504 \*\*Image available\*\*

WPI Acc No: 2000-004336/200001

XRFX Acc No: N00-003782

**Medical diagnostic assistance apparatus for pharmacy in hospitals - has display processor that processes extracted medical log information and test information of every patient related to time such that both information are displayed on same time axis**

Patent Assignee: SYSTEM YOSHII KK (SYST-N)

Number of Countries: 001 Number of Patents: 001

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
JP 11282934	A	19991015	JP 9883477	A	19980330	200001 B

Priority Applications (No Type Date): JP 9883477 A 19980330

Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
JP 11282934	A		6	G06F-019/00	

Abstract (Basic): JP 11282934 A

NOVELTY - A memory (1) stores the **medical log** information, **test** information of patients related with time. Based on selection, the medical log information and test information for every patient is extracted and is displayed on a display screen (2). A display processor (5) processes the extracted information so that medical log information and test information are displayed on same time axis.

USE - For pharmacy in hospitals.

ADVANTAGE - Enables easier and accurate diagnostic process and

thereby enables effective medical care. DESCRIPTION OF DRAWING(S) - The figure shows the block diagram of medical diagnostic assistance apparatus. (1) Memory; (2) Display screen; (5) Display processor.

Dwg.1/4

Title Terms: MEDICAL; DIAGNOSE; ASSIST; APPARATUS; PHARMACEUTICAL; HOSPITAL ; DISPLAY; PROCESSOR; PROCESS; EXTRACT; MEDICAL; LOG; INFORMATION; TEST; INFORMATION; PATIENT; RELATED; TIME; INFORMATION; DISPLAY; TIME; AXIS

Derwent Class: P33; T01

International Patent Class (Main): G06F-019/00

International Patent Class (Additional): A61G-012/00

File Segment: EPI; EngPI

11/5/16 (Item 15 from file: 350)

DIALOG(R)File 350:Derwent WPIX

(c) 2003 Thomson Derwent. All rts. reserv.

010805620 \*\*Image available\*\*

WPI Acc No: 1996-302573/199631

XRPX Acc No: N96-254595

Tracking of status and result information for medical test cards - storing unique PINs on database provided to test kit assembler, with monitoring system receiving signal from assembled test kits which are tracked updating database and checked with test laboratory and fed back to system for updating

Patent Assignee: ORTHO PHARM CORP (ORTH ); JOHNSON & JOHNSON (JOHJ )

Inventor: WELNER S

Number of Countries: 027 Number of Patents: 013

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
EP 720127	A2	19960703	EP 95309522	A	19951229	199631 B
AU 9540721	A	19960711	AU 9540721	A	19951229	199635
CZ 9503481	A3	19960814	CZ 953481	A	19951228	199639
CA 2166150	A	19960701	CA 2166150	A	19951227	199643
JP 8263577	A	19961011	JP 95352206	A	19951228	199651
US 5612870	A	19970318	US 94366785	A	19941230	199717
SG 41972	A1	19970815	SG 952407	A	19951229	199739
ZA 9511050	A	19970923	ZA 9511050	A	19951228	199744
HU 74698	T	19970228	HU 953935	A	19951229	199748
TW 315564	A	19970911	TW 96105245	A	19960502	199804
BR 9506135	A	19971223	BR 956135	A	19951229	199806
AU 691059	B	19980507	AU 9540721	A	19951229	199830
CN 1145490	A	19970319	CN 96104079	A	19960102	200104

Priority Applications (No Type Date): US 94366785 A 19941230

Patent Details:

Patent No Kind Lan Pg Main IPC Filing Notes

EP 720127 A2 E 11 G07C-009/00

Designated States (Regional): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

AU 9540721 A G06F-015/30

CZ 9503481 A3 H04M-001/70

CA 2166150 A G06F-019/00

JP 8263577 A 9 G06F-019/00

US 5612870 A 10 G06F-015/00

SG 41972 A1 A61B-005/117

ZA 9511050 A 29 G06F-000/00

HU 74698 T G06K-019/10

TW 315564 A H04L-009/32

BR 9506135 A G06K-009/62

AU 691059 B G06F-015/30 Previous Publ. patent AU 9540721

Abstract (Basic): EP 720127 A

The tracking method stores a first set of unique personal identification numbers (PINs) on the personal identification number database, and provides a digital signal representative of the PINs from the first set to a test kit assembler (130). A central monitoring system (110) receives a second digital signal from test kits actually assembled. These include a test card with one of the unique PINs. The first set is tracked and the PIN database updated w.r.t. the second digital signal.

A third digital signal is provided representing a second set of unique PINs to the test lab (160) in response to the second digital signal. The monitoring system receives a fourth digital signal from the test lab representing the test cards received at the lab from the patients. The first set of PINs are tracked by updating the PIN database and the test results database in response to the fourth signal.

USE/ADVANTAGE - For systems for tracking objects among several locations. Simultaneously tracks location and status information for several cards, facilitates collection and transmission of test results and result information to individuals being tested while, at same time, maintains anonymity of these individuals. Can identify counterfeit or unauthorised cards submitted for analysis.

Dwg.1/3

Title Terms: TRACK; STATUS; RESULT; INFORMATION; MEDICAL; TEST; CARD; STORAGE; UNIQUE; PIN; DATABASE; TEST; KIT; ASSEMBLE; MONITOR; SYSTEM; RECEIVE; SIGNAL; ASSEMBLE; TEST; KIT; TRACK; UPDATE; DATABASE; CHECK; TEST; LABORATORY; FEED; BACK; SYSTEM; UPDATE

Index Terms/Additional Words: PERSONAL; IDENTIFICATION; NUMBER

Derwent Class: P31; P85; T01; T04; T05

International Patent Class (Main): A61B-005/117; G06F-000/00 ;

G06F-015/00 ; G06F-015/30 ; G06F-019/00 ; G06K-009/62; G06K-019/10;

G07C-009/00; H04L-009/32; H04M-001/70

International Patent Class (Additional): G06F-017/30 ; G06F-017/60 ;

G06F-159/00 ; G06K-019/06; G09C-001/00

File Segment: EPI; EngPI

11/5/17 (Item 16 from file: 350)

DIALOG(R)File 350:Derwent WPIX

(c) 2003 Thomson Derwent. All rts. reserv.

010024839 \*\*Image available\*\*

WPI Acc No: 1994-292552/199436

XRPX Acc No: N94-230135

**Physiological data monitor for medical research - has output of breathing rate transducer connected to input of breathing rate signal shaper**

Patent Assignee: INKES BUSINESS INFORMATION AGENCY (INEK-R)

Inventor: DUDNIK I E; POLYAKOV A V; VASILEV A B

Number of Countries: 001 Number of Patents: 001

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
RU 2010326	C1	19940330	RU 922	A	19921020	199436 B

Priority Applications (No Type Date): RU 922 A 19921020

Patent Details:

Patent No Kind Lan Pg Main IPC Filing Notes

RU 2010326 C1 3 G06F-015/42

Abstract (Basic): RU 2010326 C

The monitor includes a microprocessor (1), a data reception unit (2), a decoder (3), an A-D converter (4), a commutator (5), a breathing rate transducer (6), a cardiac contractions rate (CCR) transducer (7), a skin-electrical reaction (SGR) transducer (8), a breathing rate signal shaper (9), a CCR signal shaper (10), a SGR signal shaper (11), a matching unit (12), and a power source (13).

USE/ADVANTAGE - For medical investigations. Cardiac contractions rate, breathing rate, and skin-electrical reaction are monitored; reduced hardware. Bul.6/30.3.94

Dwg.1/1

Title Terms: PHYSIOLOGICAL; DATA; MONITOR; MEDICAL; RESEARCH; OUTPUT;  
BREATH; RATE; TRANSDUCER; CONNECT; INPUT; BREATH; RATE; SIGNAL; SHAPE  
Derwent Class: S05; T01  
International Patent Class (Main): G06F-015/42  
File Segment: EPI

11/5/18 (Item 17 from file: 350)

DIALOG(R) File 350:Derwent WPIX  
(c) 2003 Thomson Derwent. All rts. reserv.

008843718 \*\*Image available\*\*  
WPI Acc No: 1991-347733/199148  
XRPX Acc No: N91-266310

**Activation circuit for program controlled electronic processor - contains  
2 memory modules for non-volatile erasable storage of monitor ID code  
authorising fresh data transmission**

Patent Assignee: HEWLETT-PACKARD CO (HEWP ); HEWLETT-PACKARD GMBH (HEWP )  
Inventor: DRAGER J; PARET G; DRAEGER J  
Number of Countries: 009 Number of Patents: 004  
Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
EP 457940	A	19911127	EP 90109653	A	19900521	199148 B
US 5371692	A	19941206	US 91668086	A	19910312	199503
EP 457940	B1	19960103	EP 90109653	A	19900521	199606
DE 69024638	E	19960215	DE 624638	A	19900521	199612
			EP 90109653	A	19900521	

Priority Applications (No Type Date): EP 90109653 A 19900521  
Cited Patents: DE 3417143; EP 217351; EP 338290; US 3984637; WO 8502310; EP 3638290

Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
EP 457940	A				

Designated States (Regional): BE DE FR GB IT NL SE

US 5371692 A 11 G05B-019/00

EP 457940 B1 E 16 G06F-009/445

Designated States (Regional): BE DE DK FR GB IT NL SE

DE 69024638 E G06F-009/445 Based on patent EP, 457940

Abstract (Basic): EP 457940 A

The activation circuit contains a microprocessor and peripheral hardware which has a cable (8) terminated with a connector (9) for insertion (10) into a jack (6) on the monitor box (2). Wireless transmission between antennae may be utilised instead.

One module of the microprocessor's memory receives and stores an identification code from the monitor (91). It is set up to accept only the stored code, preventing another module from transmitting to any monitor bearing a different code.

USE/ADVANTAGE - Measurement or test devices or medical



monitors . Programs can be updated or extended easily without visits from service technicians. (12pp Dwg.No.1/6)  
 Title Terms: ACTIVATE; CIRCUIT; PROGRAM; CONTROL; ELECTRONIC; PROCESSOR; CONTAIN; MEMORY; MODULE; NON; VOLATILE; ERASE; STORAGE; MONITOR; ID; CODE ; AUTHORISE; FRESH; DATA; TRANSMISSION  
 Derwent Class: S02; S05; T01  
 International Patent Class (Main): G05B-019/00; **G06F-009/445**  
 International Patent Class (Additional): **G06F-009/44**  
 File Segment: EPI

11/5/19 (Item 18 from file: 350)  
 DIALOG(R)File 350:Derwent WPIX  
 (c) 2003 Thomson Derwent. All rts. reserv.

004218564  
 WPI Acc No: 1985-045443/198508  
 XRPX Acc No: N85-033860

**Body liquid component measurement and data storage-manipulation - using small light microcomputer light analyser and solid reagent**

Patent Assignee: KYOTO DAIICHI KAGAKU KK (KYOT-N)  
 Inventor: YAMAMOTO H  
 Number of Countries: 005 Number of Patents: 007

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
DE 3428630	A	19850214	DE 3428630	A	19840803	198508 B
GB 2146764	A	19850424	GB 8419961	A	19840806	198517
GB 2146764	B	19870107				198701
US 4685059	A	19870804	US 84636302	A	19840731	198733
CA 1252824	A	19890418				198920
DE 3428630	C	19900607				199023
JP 10038879	A	19980213	JP 83144245	A	19830805	198817
			JP 96139369	A	19830805	

Priority Applications (No Type Date): JP 83144245 A 19830805; JP 96139369 A 19830805

Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
DE 3428630	A		28		
JP 10038879	A		6	G01N-033/48	Div ex application JP 83144245

Abstract (Basic): DE 3428630 A

A light beam is directed at a solid reagent applied to or impregnated with a body liquid sample. A small light analyser is placed on the analysis part and electrical signals derived from fluorescent or reflected light from the sample. The signals are fed into a microcomputer via an amplifier and analogue-to-digital converter.

The measurement data are computed using a calibration curve stored in the microcomputer or an electrical circuit. The computed data are stored with timing information in a storage circuit in the analyser. The measurement data and timing data are used for stored data processing. The output data can be fed to a display section or external device.

USE/ADVANTAGE - The method and arrangement can be used for processing measurement data for various **clinical tests** . They enable domestic **monitoring** by increasing data reliability and improving patient motivation towards self-monitoring using instrumented analysis.

0/5

Title Terms: BODY; LIQUID; COMPONENT; MEASURE; DATA; STORAGE; MANIPULATE; LIGHT; MICROCOMPUTER; LIGHT; ANALYSE; SOLID; REAGENT  
 Derwent Class: P31; S03; S05

International Patent Class (Main): G01N-033/48  
International Patent Class (Additional): A61B-005/00; A61B-010/00;  
G01N-021/55; G01N-021/75; G01N-027/44; G01N-030/96; G01N-035/00;  
**G06F-015/42** ; G06G-007/60  
File Segment: EPI; EngPI

Set	Items	Description
S1	492732	TRACK? OR TRACE? OR TRACING OR MONITOR? OR LOG? ? OR LOGGI- NG OR AUDIT?
S2	538650	STUDIES OR STUDY OR RESEARCH? OR TRIAL? OR TEST? ?
S3	503257	SAMPLE? OR EXHIBIT? OR BLOOD? OR SERUM OR GENOTYP? OR PHEN- OTYP?
S4	53927	SCIENTIST? OR RESEARCHER? OR WORKER OR ATTENDANT?
S5	22362	S2(2N) (CLINICAL OR MEDICAL?)
S6	1132	S1(5N)S5
S7	712	S6(S)S3
S8	5	S7 AND IC=G06F?
S9	37	S6 AND IC=G06F?

? show file

File 348:EUROPEAN PATENTS 1978-2003/Apr W02

(c) 2003 European Patent Office

File 349:PCT FULLTEXT 1979-2002/UB=20030417,UT=20030410

(c) 2003 WIPO/Univentio

9/3,K/1 (Item 1 from file: 348)  
DIALOG(R)File 348:EUROPEAN PATENTS  
(c) 2003 European Patent Office. All rts. reserv.

01455366

**Method & apparatus for delivering healthcare**  
**Verfahren und Anlage zur Gesundheitspflegeverabreichung**  
**Methode et dispositif pour l'administration de services de sante**

PATENT ASSIGNEE:

Pihl Limited, (3289820), Simpson Xavier Court, 20 Merchant Quay, Dublin 8  
, (IE), (Applicant designated States: all)

INVENTOR:

Sorensen, Lars, Nybyvej 18, DK-4390 Vipprod, (DK)

LEGAL REPRESENTATIVE:

Lloyd, Patrick Alexander Desmond (60081), Reddie & Grose 16 Theobalds  
Road, London WC1X 8PL, (GB)

PATENT (CC, No, Kind, Date): EP 1246113 A1 021002 (Basic)

APPLICATION (CC, No, Date): EP 2001302174 010309;

DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI;  
LU; MC; NL; PT; SE; TR

EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI

INTERNATIONAL PATENT CLASS: G06F-019/00

ABSTRACT WORD COUNT: 76

NOTE:

Figure number on first page: 1

LANGUAGE (Publication,Procedural,Application): English; English; English

FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	200240	631
SPEC A	(English)	200240	9899
Total word count - document A			10530
Total word count - document B			0
Total word count - documents A + B			10530

INTERNATIONAL PATENT CLASS: G06F-019/00

...SPECIFICATION log in.

Thus, the functionality of the module is to provide a clinical manual  
to **monitor** handling processes such as objective **tests** , **clinical**  
laboratory **tests** , invasive examinations, therapy, nursing and  
discharge.

Patient/Relative Module.

The patient is defined as a...

9/3,K/2 (Item 2 from file: 348)  
DIALOG(R)File 348:EUROPEAN PATENTS  
(c) 2003 European Patent Office. All rts. reserv.

01389438

**Registration and ordering system**  
**Registrierungs- und Bestellsystem**  
**Systeme d'enregistrement et de commande**

PATENT ASSIGNEE:

SmithKline Beecham Corporation, (2927300), One Franklin Plaza,  
Philadelphia, PA 19103, (US), (Applicant designated States: all)

INVENTOR:

Hetzel, Frank, GlaxoSmithKline. 1250 South Collegeville Road,

Collegeville, Pennsylvania 19426, (US)  
Kirsch, Richard, GlaxoSmithKline. 1250 South Collegeville Road,  
Collegeville, Pennsylvania 19426, (US)  
Schindler, Edward, GlaxoSmithKline. 1250 South Collegeville Road,  
Collegeville, Pennsylvania 19426, (US)  
Walsh, Terrence, GlaxoSmithKline. 1250 South Collegeville Road,  
Collegeville, Pennsylvania 19426, (US)

LEGAL REPRESENTATIVE:

Giddings, Peter John et al (55335), GlaxoSmithKline, Corporate  
Intellectual Property, Two New Horizons Court, Brentford, Middlesex TW8  
9EP, (GB)

PATENT (CC, No, Kind, Date): EP 1178422 A2 020206 (Basic)  
APPLICATION (CC, No, Date): EP 2001202934 010802;  
PRIORITY (CC, No, Date): US 222807 P 000804  
DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI;  
LU; MC; NL; PT; SE; TR  
EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI  
INTERNATIONAL PATENT CLASS: **G06F-017/60**  
ABSTRACT WORD COUNT: 46

LANGUAGE (Publication,Procedural,Application): English; English; English  
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	200206	653
SPEC A	(English)	200206	5691
Total word count - document A			6344
Total word count - document B			0
Total word count - documents A + B			6344

INTERNATIONAL PATENT CLASS: **G06F-017/60**

...SPECIFICATION patients in all of the study centers. Progress and  
completion data must be accumulated and **tracked** as well. Large-scale  
**clinical studies** can involve tens of different centers in several  
countries, each at a different stage of...

9/3,K/3 (Item 3 from file: 348)

DIALOG(R)File 348:EUROPEAN PATENTS

(c) 2003 European Patent Office. All rts. reserv.

01358662

**Human cysteinyl leukotriene receptor (CysLT2)**

**Menschlicher Cysteinyl Leukotrien Rezeptor 2 (CysLT2)**

**Recepteur humain de cysteinyl leukotriene 2 (CysLT2)**

PATENT ASSIGNEE:

Pfizer Limited, (204310), Ramsgate Road, Sandwich, Kent CT13 9NJ,  
GB\ (Applicant designated states: , GB)  
PFIZER INC., (200961), 235 East 42nd Street, New York, N.Y. 10017,  
US\ (Applicant designated states: , BE; CH; DE; DK; ES; FI; FR; GR; IE;  
IT; LI; LU; MC; NL; PT; SE; TR; CY)

INVENTOR:

Harland, Lee, Pfizer Global Research and Dev., Ramsgate Road, Sandwich,  
Kent CT13 9NJ, (GB)

LEGAL REPRESENTATIVE:

Hayles, James Richard (75142), Pfizer Limited, Patents Department,  
Ramsgate Road, Sandwich Kent CT13 9NJ, (GB)

PATENT (CC, No, Kind, Date): EP 1158050 A1 011128 (Basic)  
APPLICATION (CC, No, Date): EP 2001303090 010330;  
PRIORITY (CC, No, Date): GB 8504 000405  
DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI;

Bode Akintola 24-Apr-03

LU; MC; NL; PT; SE; TR  
EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI  
INTERNATIONAL PATENT CLASS: C12N-015/12; C12N-015/74; C12N-009/00;  
C12N-005/10; C12N-001/20; C07K-014/72; C07H-021/02; C07K-016/28;  
G01N-033/50; G01N-033/53; A61K-038/22; A61K-039/395; C30B-029/58;  
**G06F-017/50**

ABSTRACT WORD COUNT: 58

NOTE:

Figure number on first page: NONE

LANGUAGE (Publication,Procedural,Application): English; English; English  
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	200148	1630
SPEC A	(English)	200148	23831
Total word count - document A			25461
Total word count - document B			0
Total word count - documents A + B			25461

...INTERNATIONAL PATENT CLASS: **G06F-017/50**

...SPECIFICATION evaluate the efficacy of a particular therapeutic treatment regime and may be used in animal studies , in clinical trials, or in monitoring the treatment of an individual patient. In order to provide a basis for the diagnosis...

**9/3,K/4** (Item 4 from file: 348)

DIALOG(R) File 348:EUROPEAN PATENTS

(c) 2003 European Patent Office. All rts. reserv.

01343763

**Noncontact transmitting apparatus**

**Kontaktlose Übertragungsvorrichtung**

**Appareil de transmission sans contact**

PATENT ASSIGNEE:

MITSUBISHI DENKI KABUSHIKI KAISHA, (208589), 2-3, Marunouchi 2-chome,  
Chiyoda-ku, Tokyo 100-8310, (JP), (Applicant designated States: all)

INVENTOR:

Takeda, Munehisa, c/o Mitsubishi Denki K.K., 2-3, Marunouchi 2-chome,  
Chiyoda-ku, Tokyo 100-8310, (JP)

Aizawa, Jyunichi, c/o Mitsubishi Denki K.K., 2-3, Marunouchi 2-chome,  
Chiyoda-ku, Tokyo 100-8310, (JP)

Araki, Takeshi, c/o Mitsubishi Denki K.K., 2-3, Marunouchi 2-chome,  
Chiyoda-ku, Tokyo 100-8310, (JP)

Shoji, Hideaki, c/o Mitsubishi Denki K.K., 2-3, Marunouchi 2-chome,  
Chiyoda-ku, Tokyo 100-8310, (JP)

LEGAL REPRESENTATIVE:

Sajda, Wolf E., Dipl.-Phys. et al (9956), MEISSNER, BOLTE & PARTNER  
Postfach 86 06 24, 81633 Munchen, (DE)

PATENT (CC, No, Kind, Date): EP 1148406 A2 011024 (Basic)  
EP 1148406 A3 020619

APPLICATION (CC, No, Date): EP 2001108872 010409;

PRIORITY (CC, No, Date): JP 2000108469 000410

DESIGNATED STATES: DE; FR; GB

EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI

INTERNATIONAL PATENT CLASS: **G06F-001/16** ; **G06F-003/00** ; H04M-001/215

ABSTRACT WORD COUNT: 283

NOTE:

Figure number on first page: 1

LANGUAGE (Publication,Procedural,Application): English; English; English  
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	200143	1071
SPEC A	(English)	200143	5307
Total word count - document A			6378
Total word count - document B			0
Total word count - documents A + B			6378

INTERNATIONAL PATENT CLASS: G06F-001/16 ...

... G06F-003/00

...SPECIFICATION cellular phone or mobile personal computer, a game machine, an AV (audio-visual) machine, a **medical** device, an **industrial** machine and an environmental **monitoring** device.

Description of Related Art

Conventionally, although a cellular phone integrating a camera is known

...

9/3,K/5 (Item 5 from file: 348)

DIALOG(R)File 348:EUROPEAN PATENTS

(c) 2003 European Patent Office. All rts. reserv.

01312196

TRACKING OF CLINICAL STUDY SAMPLES, INFORMATION AND RESULTS  
LOCALISATION D'ECHANTILLONS D'ETUDES CLINIQUES, D'INFORMATIONS ET DE  
RESULTATS

PATENT ASSIGNEE:

PPGx, Inc., (3359140), 3900 Paramount Parkway, Morrisville, NC 27560,  
(US), (Applicant designated States: all)

INVENTOR:

MARKIDAN, Igor, 1109 Willowdale Dr., Cherry Hill, NJ 08003-2834, (US)

OBEROI, Himanshu, 49 N. Gate Park, Newton, MA 02465, (US)

MELNICK, Jerald, H., 6 Cameron Rd., Wayland, MA 01778, (US)

PATENT (CC, No, Kind, Date):

WO 2001043038 010614

APPLICATION (CC, No, Date): EP 2000984392 001213; WO 2000US33938 001213

PRIORITY (CC, No, Date): US 170432 P 991213

DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI;  
LU; MC; NL; PT

EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI

INTERNATIONAL PATENT CLASS: G06F-017/60

LANGUAGE (Publication,Procedural,Application): English; English; English

TRACKING OF CLINICAL STUDY SAMPLES, INFORMATION AND RESULTS

INTERNATIONAL PATENT CLASS: G06F-017/60

9/3,K/6 (Item 6 from file: 348)

DIALOG(R)File 348:EUROPEAN PATENTS

(c) 2003 European Patent Office. All rts. reserv.

01281460

Automated collection and analysis patient care system and method for  
diagnosing and monitoring the outcomes of atrial fibrillation

Automatisiertes Sammlungs und Analyse- Patienten ,Pflegesystem und  
Verfahren zur Diagnose und Ueberwachung von Vorhof-fibrillationsergebni  
sse

**Systeme de gestion de soins aux patients avec collection et analyse  
automatique et methode de la diagnose et surveillance des resultats de  
la fibrillation auriculaire**

**PATENT ASSIGNEE:**

Cardiac Intelligence Corporation, (3179130), 2518 Constance Drive West,  
Seattle, Washington 98199-3017, (US), (Applicant designated States:  
all)

**INVENTOR:**

Bardy, Gust H., 2518 Constance Drive West, Seattle, Washington 98199-3017  
, (US)

**LEGAL REPRESENTATIVE:**

Hanna, Peter William Derek (72342), Peter Hanna Associates 11 Mespil Road  
, Dublin 4, (IE)

PATENT (CC, No, Kind, Date): EP 1102199 A2 010523 (Basic)  
EP 1102199 A3 020522

APPLICATION (CC, No, Date): EP 2000650197 001116;

PRIORITY (CC, No, Date): US 441623 991116

DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI;  
LU; MC; NL; PT; SE; TR

EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI

INTERNATIONAL PATENT CLASS: **G06F-019/00**

ABSTRACT WORD COUNT: 130

**NOTE:**

Figure number on first page: 1

LANGUAGE (Publication,Procedural,Application): English; English; English

**FULLTEXT AVAILABILITY:**

Available Text	Language	Update	Word Count
CLAIMS A	(English)	200121	1900
SPEC A	(English)	200121	14154
Total word count - document A			16054
Total word count - document B			0
Total word count - documents A + B			16054

INTERNATIONAL PATENT CLASS: **G06F-019/00**

...SPECIFICATION monitoring service having the capability to remotely and  
continuously collect and analyze external or implantable **medical** device  
measures, **atrial** fibrillation detection, prevention and **tracking**  
regression from therapeutic maneuvers become feasible.

Still other embodiments of the present invention will become...

**9/3,K/7 (Item 7 from file: 348)**

DIALOG(R)File 348:EUROPEAN PATENTS

(c) 2003 European Patent Office. All rts. reserv.

01116727

**CLINICAL TRIAL DATA MANAGEMENT SYSTEM AND METHOD**

**DATENVERWALTUNGSSYSTEM UND VERFAHREN FUR KLINISCHE STUDIEN**

**SYSTEME ET PROCEDE DE GESTION DE DONNEES D'ESSAIS CLINIQUES**

**PATENT ASSIGNEE:**

Phase Forward Inc., (2905670), 51 Winchester Street, Newton, MA 02461,  
(US), (Proprietor designated states: all)

**INVENTOR:**

BLEICHER, Paul, A., 174 Mt. Vernon Street, Newton, MA 02165, (US)

STAMOS, Nicholas, 22 Jeannette Avenue, Belmont, MA 02478, (US)

KLOFFT, Jeffrey, P., 33 Hamilton Circle, Marlborough, MA 01752, (US)

DALE, Richard, M., 117 Russell Street, Newton, MA 02165, (US)

**LEGAL REPRESENTATIVE:**



Driver, Virginia Rozanne et al (58902), Page White & Farrer 54 Doughty  
Street, London WC1N 2LS, (GB)  
PATENT (CC, No, Kind, Date): EP 1082693 A2 010314 (Basic)  
EP 1082693 B1 021106  
WO 99063473 991209  
APPLICATION (CC, No, Date): EP 99927196 990603; WO 99US12406 990603  
PRIORITY (CC, No, Date): US 92441 980605  
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FI; FR; GB; IE; IT; LI; NL; SE  
INTERNATIONAL PATENT CLASS: G06F-019/00  
NOTE:

No A-document published by EPO  
LANGUAGE (Publication,Procedural,Application): English; English; English  
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	200245	1294
CLAIMS B	(German)	200245	1372
CLAIMS B	(French)	200245	1533
SPEC B	(English)	200245	10916
Total word count - document A			0
Total word count - document B			15115
Total word count - documents A + B			15115

INTERNATIONAL PATENT CLASS: G06F-019/00

...SPECIFICATION review roles to be performed at the Clinical Research  
Organization (CRO) and/or sponsor. The **Clinical Research Associate**  
(CRA), **Clinical Data Manager**, **Medical Monitor** , and Clinical Project  
Manager review the data that is generated by the investigator sites for  
...

9/3,K/8 (Item 8 from file: 348)  
DIALOG(R)File 348:EUROPEAN PATENTS  
(c) 2003 European Patent Office. All rts. reserv.

00785927

Automated system for identifying authorized system users  
Automatisiertes System zur Identifikation von Systembenutzern  
Systeme automatise pour identifier des utilisateurs autorises du systeme  
PATENT ASSIGNEE:

ORTHO PHARMACEUTICAL CORPORATION, (216161), U.S. Route no. 202, Raritan,  
NJ 08869, (US), (applicant designated states:  
AT;BE;CH;DE;DK;ES;FR;GB;GR;IE;IT;LI;LU;NL;PT;SE)

INVENTOR:

Welner, Stephen, 15 Davis Court, Martinsville, New Jersey 08836, (US)

LEGAL REPRESENTATIVE:

Fisher, Adrian John et al (52611), CARPMAELS & RANSFORD 43 Bloomsbury  
Square, London WC1A 2RA, (GB)

PATENT (CC, No, Kind, Date): EP 734000 A2 960925 (Basic)  
EP 734000 A3 980527

APPLICATION (CC, No, Date): EP 95309521 951229;

PRIORITY (CC, No, Date): US 367535 941230

DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LI; LU; NL;  
PT; SE

INTERNATIONAL PATENT CLASS: G07C-009/00; G06F-001/00 ; H04L-029/06

ABSTRACT WORD COUNT: 211

LANGUAGE (Publication,Procedural,Application): English; English; English  
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
----------------	----------	--------	------------

CLAIMS A	(English)	EPAB96	625
SPEC A	(English)	EPAB96	2684
Total word count - document A			3309
Total word count - document B			0
Total word count - documents A + B			3309

...INTERNATIONAL PATENT CLASS: G06F-001/00

...SPECIFICATION caller.

As described more fully in U.S. Patent Appl. No. (unknown), entitled "System for Tracking Secure Medical Test Cards" the contents of which is incorporated herein in its entirety by reference; a central...

9/3,K/9 (Item 9 from file: 348)  
 DIALOG(R)File 348:EUROPEAN PATENTS  
 (c) 2003 European Patent Office. All rts. reserv.

00768209

Call routing and handling system for conveying confidential medical test result information to anonymous callers

System fur die Leitweglenkung und die Verarbeitung von Telefongesprachen zur Ubermittlung vertraulicher Informationen medizinische Testergebnisse betreffend an

Systeme d'acheminement et de traitement d'appels pour la transmission d'informations confidentielles concernant des resultats de tests medicaux a un corresponda

PATENT ASSIGNEE:

ORTHO PHARMACEUTICAL CORPORATION, (216161), U.S. Route no. 202, Raritan, NJ 08869, (US), (applicant designated states: AT;BE;CH;DE;DK;ES;FR;GB;GR;IE;IT;LI;LU;NL;PT;SE)

INVENTOR:

Welner, Stephen, 15 Davis Court, Martinsville, New Jersey 08836, (US)  
 Millenson, Elliot, 15 Ashington Club Road, Far Hills, New Jersey 07931, (US)

Strongin, Wendy, 15 Ashington Club Road, Far Hills, New Jersey 07931, (US)

LEGAL REPRESENTATIVE:

Fisher, Adrian John (52611), CARPMAELS & RANSFORD 43 Bloomsbury Square, London WC1A 2RA, (GB)

PATENT (CC, No, Kind, Date): EP 720111 A2 960703 (Basic)  
 EP 720111 A3 970219

APPLICATION (CC, No, Date): EP 95309519 951229;

PRIORITY (CC, No, Date): US 366796 941230

DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LI; LU; NL; PT; SE

INTERNATIONAL PATENT CLASS: H04Q-003/00; H04M-003/50; G06F-019/00

ABSTRACT WORD COUNT: 230

LANGUAGE (Publication,Procedural,Application): English; English; English  
 FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPAB96	608
SPEC A	(English)	EPAB96	5869
Total word count - document A			6477
Total word count - document B			0
Total word count - documents A + B			6477

...INTERNATIONAL PATENT CLASS: G06F-019/00

...SPECIFICATION described in U.S. Patent Appl. No. (unknown), filed simultaneously herewith, and entitled "System for **Tracking Medical Test Cards**," the contents of which is hereby incorporated in its entirety herein by reference. In...

9/3,K/10 (Item 10 from file: 348)  
DIALOG(R)File 348:EUROPEAN PATENTS  
(c) 2003 European Patent Office. All rts. reserv.

00755344

**Method and apparatus for administering clinical trial material**  
**Verfahren und Vorrichtung zum Verwalten von klinischem Versuchsmaterial**  
**Methode et arrangement pour la gestion de produit pour essais cliniques**  
PATENT ASSIGNEE:

ELI LILLY AND COMPANY, (204942), Lilly Corporate Center, Indianapolis, Indiana 46285, (US), (applicant designated states: AT;BE;CH;DE;DK;ES;FR;GB;GR;IE;IT;LI;LU;NL;PT;SE)

INVENTOR:

Jeatran, Thomas L., 3128 River Bay Drive North, Indianapolis, Indiana 46240, (US)

Tamura, Roy N., 7309 Eastwick Lane, Indianapolis, Indiana 46256, (US)  
Solenberg, James M., Jr., 10116 Seabreeze Way, Indianapolis, Indiana 46256, (US)

LEGAL REPRESENTATIVE:

Tapping, Kenneth George et al (52302), Lilly Industries Limited European Patent Operations Erl Wood Manor, Windlesham Surrey GU20 6PH, (GB)

PATENT (CC, No, Kind, Date): EP 710917 A1 960508 (Basic)

APPLICATION (CC, No, Date): EP 95307791 951101;

PRIORITY (CC, No, Date): US 334411 941104

DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LI; LU; NL; PT; SE

INTERNATIONAL PATENT CLASS: G06F-019/00

ABSTRACT WORD COUNT: 293

LANGUAGE (Publication,Procedural,Application): English; English; English  
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPAB96	240
SPEC A	(English)	EPAB96	8220
Total word count - document A			8460
Total word count - document B			0
Total word count - documents A + B			8460

INTERNATIONAL PATENT CLASS: G06F-019/00

...SPECIFICATION through clinical trial studies, and more specifically, to a method for assigning treatments, dispensing drugs, **monitoring clinical trial** materials, and obtaining data from clinical trials.

Background of the Invention

Clinical trials of new...

...comply with all aspects of Good Manufacturing Practices (GMP) requirements.

Traditional methods of conducting blind **clinical studies** include a group of patients **monitored** by an investigator or investigators. For example, in a study with a total of 300...

9/3,K/11 (Item 11 from file: 348)

DIALOG(R)File 348:EUROPEAN PATENTS  
(c) 2003 European Patent Office. All rts. reserv.

00413629

**Activating circuit**

**Aktivierungsschaltung**

**Circuit d'activation**

**PATENT ASSIGNEE:**

Hewlett-Packard GmbH, (292551), Postfach 14 30, D-71004 Boblingen, (DE),  
(applicant designated states: BE;DE;DK;FR;GB;IT;NL;SE)

**INVENTOR:**

Drager, Jurgen, Sandackerstrasse 82, D-72070 Tübingen, (DE)  
Paret, Gunter, Hugo-Wolf-Strasse 34, D-71083 Herrenberg, (DE)

**LEGAL REPRESENTATIVE:**

Kurz, Peter (57961), Hewlett-Packard GmbH, Europ. Patent- und  
Lizenzabteilung, Herrenberger Strasse 130, D-71034 Boblingen, (DE)

PATENT (CC, No, Kind, Date): EP 457940 A1 911127 (Basic)

EP 457940 B1 960103

APPLICATION (CC, No, Date): EP 90109653 900521;

PRIORITY (CC, No, Date): EP 90109653 900521

DESIGNATED STATES: BE; DE; DK; FR; GB; IT; NL; SE

INTERNATIONAL PATENT CLASS: **G06F-009/445**

ABSTRACT WORD COUNT: 166

LANGUAGE (Publication,Procedural,Application): English; English; English

**FULLTEXT AVAILABILITY:**

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPAB96	835
CLAIMS B	(German)	EPAB96	930
CLAIMS B	(French)	EPAB96	937
SPEC B	(English)	EPAB96	4749
Total word count - document A			0
Total word count - document B			7451
Total word count - documents A + B			7451

INTERNATIONAL PATENT CLASS: **G06F-009/445**

...SPECIFICATION Patent Application EP-A-338 290.

A multiplicity of electronic devices, such as measuring devices,  
**medical monitors** or **test** devices, perform their functions nowadays  
under control of a microprocessor. Although the measurement pickups - e  
...

**9/3,K/12 (Item 1 from file: 349)**

DIALOG(R)File 349:PCT FULLTEXT

(c) 2003 WIPO/Univentio. All rts. reserv.

01000052 \*\*Image available\*\*

**TIMELINE FORECASTING FOR CLINICAL TRIALS**

**PREVISION DE CALENDRIER D'ESSAIS CLINIQUES**

**Patent Applicant/Assignee:**

FASTTRACK SYSTEMS INC, 1825 South Grant Street, Suite 310, San Mateo, CA  
94402-2660, US, US (Residence), US (Nationality)

**Inventor(s):**

KAHN Michael G, 3980 Greenbriar Boulevard, Boulder, CO 80303, US,  
MISCHKE-REEDS Michael, 44 Brentwood Avenue, San Francisco, CA 94127, US,  
NGUYEN John H, 2931 Winwood Way, San Jose, CA 95148, US,

**Legal Representative:**

WOLFELD Warren S (et al) (agent), Haynes Beffel & Wolfeld LLP, P.O. Box  
366, Half Moon Bay, CA 94019, US,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200330062 A1 20030410 (WO 0330062)  
Application: WO 2002US30424 20020925 (PCT/WO US0230424)  
Priority Application: US 2001970182 20011003

Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU  
CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP  
KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO  
RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW  
(EP) AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR  
(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG  
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW  
(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Filing Language: English

Fulltext Word Count: 24713

Main International Patent Class: G06F-017/60

Fulltext Availability:

Detailed Description

Detailed Description

... of a particular protocol. The system reports this information to study  
sponsors, who can then **monitor** the progress of an overall **clinical**  
**trial** in near-real-time, and to the central authority which can then  
generate performance metrics...

9/3,K/13 (Item 2 from file: 349)

DIALOG(R)File 349:PCT FULLTEXT

(c) 2003 WIPO/Univentio. All rts. reserv.

00972272

PROCESS

PROCEDE

Patent Applicant/Assignee:

GLAXO GROUP LIMITED, Glaxo Wellcome House, Berkeley Avenue, Greenford,  
Middlesex UB6 0NN, GB, GB (Residence), GB (Nationality), (For all  
designated states except: US)  
SMITHKLINE BEECHAM P L C, 980 Great West Road, Brentford, Middlesex TW8  
9GS, GB, GB (Residence), GB (Nationality), (For all designated states  
except: US)

Patent Applicant/Inventor:

CARTER Paul Laurence, GlaxoSmithKline, New Frontiers Science Park South,  
Harlow, Essex CM19 5AW, GB, GB (Residence), GB (Nationality),  
(Designated only for: US)  
DAY Stephen, GlaxoSmithKline, New Frontiers Science Park South, Harlow,  
Essex CM19 5AW, GB, GB (Residence), GB (Nationality), (Designated only  
for: US)  
EVANS Peter Graham, GlaxoSmithKline, New Frontiers Science Park South,  
Harlow, Essex CM19 5AW, GB, GB (Residence), GB (Nationality),  
(Designated only for: US)  
GEORGE Lesley Julia, GlaxoSmithKline, New Frontiers Science Park South,  
Harlow, Essex CM19 5AW, GB, GB (Residence), GB (Nationality),  
(Designated only for: US)

Legal Representative:

WALKER Ralph Francis (agent), Corporate Intellectual Property,  
GlaxoSmithKline, 980 Great West Road (CN925.1), Brentford, Middlesex  
TW8 9GS, GB,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200301429 A2 20030103 (WO 0301429)  
Application: WO 2002EP6895 20020621 (PCT/WO EP0206895)

Priority Application: GB 200115414 20010623  
Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU  
CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP  
KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO  
RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW  
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR  
(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG  
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW  
(EA) AM AZ BY KG KZ MD RU TJ TM  
Publication Language: English  
Filing Language: English  
Fulltext Word Count: 9572  
Main International Patent Class: G06F-019/00  
Fulltext Availability:  
Detailed Description

#### Detailed Description

I

##### Process

The invention relates to a method of automatically **tracking** compliance in a **clinical trial** process.

A **clinical trial** is the testing of a medicament or drug entity in humans in order to determine...is a further object of the present invention to provide a method for identifying and **tracking** such containers throughout the **clinical trial** process and to maintain a full electronic data record of each container by which a method for automatically **tracking** compliance in a **clinical trial** process involving one or more operations comprising.

selecting a container;  
associating an identifier with the...trial. The patient identifiers can also form an important link in facilitating a complete electronic **audit** trail for each **clinical trial** sample/drug product. Patient identifiers may comprise a 'Smart Card' having a memory wherein the...of an RFID tag.

Figure 3 is a flow diagram of a method for **tracking** compliance in a **clinical trial** process.

Figure 4 is a schematic diagram of a system employing a method for **tracking** compliance in a **clinical trial** process.

Figures 5a & b depict a method for selecting a first and a ...process monitored from a centralised data management system.

A flow diagram of a method for **tracking** compliance in a **clinical trial** process is shown in Figure 3. The method begins by selecting 230 a first...container has been completed 251.

A schematic representation of a system employing a method for **tracking** compliance in a **clinical trial** process is shown in Figure 4. The diagram illustrates a simplified process for filling a...

9/3,K/14 (Item 3 from file: 349)  
DIALOG(R)File 349:PCT FULLTEXT  
(c) 2003 WIPO/Univentio. All rts. reserv.

00967455 \*\*Image available\*\*

SYSTEM AND METHOD FOR BRIDGING A CLINICAL REMOTE DATA ENTRY PRODUCT TO A  
BOCK-END CLINICAL DATA MANAGEMENT SYSTEM  
SYSTEME ET PROCEDE DE LIAISON D'UN PRODUIT D'ENTREE DE DONNEES CLINIQUES  
DISTANT A UN SYSTEME DE GESTION DES DONNEES CLINIQUES ARRIERE

Patent Applicant/Assignee:

F HOFFMANN-LA ROCHE AG, 124 Grenzacherstrasse, CH-4070 Basel, CH, CH  
(Residence), CH (Nationality), (For all designated states except: US)

Patent Applicant/Inventor:

KLOSS Siebgert R, 2453 Villa Nueva Way, Mountain View, CA 94040, US, US  
(Residence), US (Nationality), (Designated only for: US)  
BORNHAUSEN Anja, Loewenstrasse 17, 30175 Hannover, DE, DE (Residence), DE  
(Nationality), (Designated only for: US)  
EGAR John W, 16240 Ralston Way, Boulder Creek, CA 95006, US, US  
(Residence), US (Nationality), (Designated only for: US)  
SAYER Richard, 1063 Morse Avenue, Apt. 307-25, Sunnyvale, CA 94089, US,  
US (Residence), GB (Nationality), (Designated only for: US)  
O'CONNOR Peter J, 1246 Morton Avenue, Santa Clara, CA 95051, US, US  
(Residence), US (Nationality), (Designated only for: US)  
DE SCHEPPER HUGO, 51 Hooiveld, 2870 Purrs, BE, BE (Residence), BE  
(Nationality), (Designated only for: US)

Legal Representative:

FRIEBEL Thomas E (et al) (agent), Pennie & Edmonds, 1155 Avenue of the  
Americas, New York, NY 10036, US,

Patent and Priority Information (Country, Number, Date):

Patent: WO 2002101496 A2 20021219 (WO 02101496)  
Application: WO 2002US17799 20020606 (PCT/WO US0217799)  
Priority Application: US 2001876928 20010608

Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU  
CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP  
KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO  
RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW  
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR  
(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG  
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW  
(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Filing Language: English

Fulltext Word Count: 28140

Main International Patent Class: G06F

Fulltext Availability:

Detailed Description

Detailed Description

... from hiferMed, Ltd., London UK, requires that a macro study definition  
be prepared for each **clinical trial monitored** by MACRO. The macro  
study definition is a collection of metatables that describe the patient  
...end CDMS. The back-end clinical definition is a data structure that is  
used to **track** all the patients in a **clinical study**. The back-end  
clinical definition is designed in accordance with the specifications of  
the particular...

9/3,K/15 (Item 4 from file: 349)

DIALOG(R)File 349:PCT FULLTEXT

(c) 2003 WIPO/Univentio. All rts. reserv.

00939349 \*\*Image available\*\*

METHOD AND APPARATUS FOR DELIVERING HEALTHCARE

PROCEDE ET APPAREIL DE FOURNITURE DE SOINS DE SANTE

Patent Applicant/Assignee:

PIHL LIMITED, Simpson Xavier Court, 20 Merchant Quay, Dublin, IE, IE  
(Residence), IE (Nationality), (For all designated states except: US)

Patent Applicant/Inventor:

SORENSEN Jesper Leck, Skrouten 7, DK-8660 Skenderborg, DK, DK (Residence)  
, DK (Nationality), (Designated only for: US)

SORENSEN Lars, Nybyvej 18, DK-4390 Vipprod, DK, DK (Residence), DK  
(Nationality), (Designated only for: US)

Legal Representative:

LLOYD Patrick Alexander Desmond (agent), Reddie & Grose, 16 Theobalds  
Road, London WC1X 8PL, GB,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200273497 A2 20020919 (WO 0273497)

Application: WO 2002IB1811 20020308 (PCT/WO IB0201811)

Priority Application: EP 2001302174 20010309; US 2001873761 20010604

Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU

CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP

KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO

RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW

(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Filing Language: English

Fulltext Word Count: 12613

Main International Patent Class: G06F-019/00

Fulltext Availability:

Detailed Description

Detailed Description

... log in.

Thus, the functionality of the module is to provide a  
clinical manual to **monitor** handling processes such as  
objective **tests**, **clinical** laboratory **tests**, invasive  
examinations, therapy, nursing and discharge.

Patient/Relative Module.

The patient is defined as a...

9/3,K/16 (Item 5 from file: 349)

DIALOG(R)File 349:PCT FULLTEXT

(c) 2003 WIPO/Univentio. All rts. reserv.

00924752

SYSTEM AND METHOD FOR EMERGENCY COMMUNICATION BETWEEN AN IMPLANTABLE  
MEDICAL AND A REMOTE COMPUTER SYSTEM OF HEALTH CARE PROVIDER  
SYSTEME ET PROCEDE DE COMMUNICATION URGENTE ENTRE UN DISPOSITIF MEDICAL  
IMPLANTABLE ET UN SYSTEME INFORMATIQUE POUR FOURNISSEUR DE SOINS DE  
SANTE

Patent Applicant/Assignee:

MEDTRONIC INC, 710 Medtronic Parkway NE, Minneapolis, MN 55432, US, US  
(Residence), US (Nationality)

Inventor(s):

HALLER Markus, 2848 Webster Avenue South, St. Louis Park, MN 55416, US,

FEREK-PETRIC Bozidar, Sovinec 17, 10000 Zagreb, HR,

DONDERS Adrianus P, Chemin Champs Rosset 3, CH-1297 Founex, CH,



Legal Representative:

WOODS Thomas F (et al) (agent), Medtronic, Inc. LC340, 710 Medtronic Parkway NE, Minneapolis, MN 55432, US,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200257994 A2 20020725 (WO 0257994)

Application: WO 2002US1542 20020116 (PCT/WO US0201542)

Priority Application: US 2001764700 20010118

(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

Publication Language: English

Filing Language: English

Fulltext Word Count: 30387

Main International Patent Class: G06F-019/00

Fulltext Availability:

Detailed Description

Detailed Description

... remote system 13 0 or remote health care  
provider 13 6 initiates communication for patient **monitoring** , **clinical**

**study monitoring** , therapeutic, **clinical outcome study** or other  
purposes to  
thereby minimize unnecessary patient-physician or patient-hospital  
interaction.

Phone or...present invention may also be configured and adapted to more  
efficiently and cost-effectively administer **clinical monitoring**  
**studies** and **clinical outcome studies** . In accordance with 1 0 one  
embodiment of the present invention, IMDs implanted in patients...  
...00 or mobile phones or PDAs 1 1 0, where patients 5 are participating in  
**clinical outcome studies** and/or **clinical monitoring studies** ,  
are interrogated for data required or desired for purposes of completing  
such studies.

Devices 1...

9/3,K/17 (Item 6 from file: 349)

DIALOG(R)File 349:PCT FULLTEXT

(c) 2003 WIPO/Univentio. All rts. reserv.

00924377 \*\*Image available\*\*

**SYSTEM AND METHOD OF AUTOMATED INVOICING FOR COMMUNICATIONS BETWEEN AN  
IMPLANTABLE MEDICAL DEVICE AND A REMOTE COMPUTER SYSTEM FOR HEALTH  
PROVIDER**

**SYSTEME ET PROCEDE DE FACTURATION AUTOMATISEE DE COMMUNICATIONS ETABLIES  
ENTRE UN DISPOSITIF MEDICAL IMPLANTABLE ET UN SYSTEME INFORMATISE  
ELOIGNE POUR APPAREIL DE SOINS DE SANTE**

Patent Applicant/Assignee:

MEDTRONIC INC, 710 Medtronic Parkway NE, Minneapolis, MN 55432, US, US  
(Residence), US (Nationality)

Inventor(s):

HALLER Markus, 2848 Webster Avenue South, St. Louis Park, MN 55416, US,  
FEREK-PETRIC Bozidar, Sovenic 17, 10000 Zagreb, HR,  
DONDERS Adrianus P, Ch. Champs Rosset 3, CH-1297 Founex, CH,

Legal Representative:

WOODS Thomas F (et al) (agent), Medtronic, Inc. LC340, 710 Medtronic Parkway NE, Minneapolis, MN 55432, US,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200256762 A2-A3 20020725 (WO 0256762)

Application: WO 2002US1544 20020116 (PCT/WO US0201544)  
Priority Application: US 2001765218 20010118  
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR  
Publication Language: English  
Filing Language: English  
Fulltext Word Count: 30136

Main International Patent Class: G06F-019/00  
Fulltext Availability:  
Detailed Description

Detailed Description

... I 10, remote system 130 or remote health care  
provider 136 initiates communication for patient **monitoring , clinical  
study 1 0 monitoring , therapeutic, clinical outcome study** or  
other purposes to thereby minimize unnecessary patient-physician or  
patient-hospital interaction.

Phone or...may also be configured and adapted to more efficiently and  
cost-effectively 1 5 administer **clinical monitoring studies** and  
**clinical outcome studies** . In accordance with one embodiment of the  
present invention, IMDs implanted in patients 5 and...

...00 or mobile phones or PDAs 1 1 0, where patients 5 are participating in  
**clinical outcome studies** and/or **clinical monitoring studies** ,  
are interrogated for data required or desired for purposes of completing  
such studies.

Devices IO...

9/3,K/18 (Item 7 from file: 349)  
DIALOG(R)File 349:PCT FULLTEXT  
(c) 2003 WIPO/Univentio. All rts. reserv.

00917687 \*\*Image available\*\*

**METHOD FOR DRUG DEVELOPMENT USING INDIVIDUAL PATIENT RESPONSE**  
**SYSTEME ET PROCEDE D'ELABORATION DE MEDICAMENTS DESTINES A UNE UTILISATION**  
**SELECTIVE DE MEDICAMENTS CHEZ DES INDIVIDUS, PATIENTS REpondant AU**  
**TRAITEMENT ET APPLICATIONS DU PROCEDE DANS DES SOINS MEDICAUX**

Patent Applicant/Inventor:

BECKER Robert E, 2523 Aspen Spring Drive, Park City, UT 84060, US, US  
(Residence), US (Nationality)

Legal Representative:

GIARRATANA Mark D (et al) (agent), Cummings & Lockwood, Granite Square,  
700 State Street, P.O. Box 1960, New Haven, CT 06509-1960, US,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200251354 A2-A3 20020704 (WO 0251354)

Application: WO 2001US49457 20011026 (PCT/WO US0149457)

Priority Application: US 2000258262 20001226; US 2001274981 20010312; US  
2001301526 20010628

Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU  
CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP  
KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD  
SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW

(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Filing Language: English  
Fulltext Word Count: 8776

International Patent Class: G06F-017/60 ...

... G06F-017/30  
Fulltext Availability:  
Detailed Description

Detailed Description  
... electronic medical record system routinely queries a patient and enters these assessments with the laboratory **studies** and **clinical** findings to **monitor** the current treatment in terms of whether it offers the patient the highest probability of...

9/3,K/19 (Item 8 from file: 349)  
DIALOG(R)File 349:PCT FULLTEXT  
(c) 2003 WIPO/Univentio. All rts. reserv.

00910745 \*\*Image available\*\*  
**METHOD AND APPARATUS OF ASSURING INFORMED CONSENT WHILE CONDUCTING SECURE CLINICAL TRIALS**  
**PROCEDE ET DISPOSITIF POUR GARANTIR UN CONSENTEMENT ECLAIRE PENDANT DES ESSAIS CLINIQUES SECURISES**

Patent Applicant/Assignee:  
MEDIDATA SOLUTIONS INC, 30 East 60th Street, Suite 1007, New York, NY 10022, US, US (Residence), US (Nationality), (For all designated states except: US)

Patent Applicant/Inventor:  
DE VRIES Glen M, 442 East 9th Street, Apt. 1A, New York NY 10009, US, US (Residence), US (Nationality), (Designated only for: US)  
IKEGUCHI Edward F, 36 Blossom Terrace, Larchmont, NY 10538, US, US (Residence), US (Nationality), (Designated only for: US)  
TE Alexis E, 111 Mill Spring Road, Manhasset, NY 11030, US, US (Residence), US (Nationality), (Designated only for: US)

Legal Representative:  
DIPPERT William H (et al) (agent), Reed Smith LLP, 375 Park Avenue, New York, NY 10152, US,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200244868 A2-A3 20020606 (WO 0244868)  
Application: WO 2001US51091 20011113 (PCT/WO US0151091)  
Priority Application: US 2000247314 20001110

Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW  
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR  
(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG  
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW  
(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English  
Filing Language: English  
Fulltext Word Count: 15178

Main International Patent Class: G06F-017/30  
Fulltext Availability:  
Detailed Description  
Claims

#### Detailed Description

... Over time CROs compounded other value-added services to encompass a spectrum of services, including **clinical trial** coordination, **monitoring** of data collection, identification of quality research trial investigators and sites, and centralized laboratory testing...paper document. This creates ample of opportunity for fraud and an obvious need for strict **monitoring** . As the **clinical research** field looks more to digital data capture and transmission, there is a greater need to...

...investigators in turn will select the trial participants or patients to be enrolled in the **clinical trial** . The **trial monitors** observe the conduct of the clinical trials to detect any deviations from the procedural guidelines...code field 270i comprising a plurality of random digits.

The current methods of administering a **clinical trial** involve **monitoring** the trial centers to assure research integrity. The basic role of the trial monitor is...submitted by the trial investigator corresponds to the source documentation, i.e., the patient's **medical** record. The **trial** monitor verifies whether the trial investigator has provided the proper informed consent and that the trial...will be able to have a real-time "bird's eye view" of the ongoing **clinical trial** . After **logging** in step 202, the trial administrator will be asked to authenticate himself or herself as...

#### Claim

... enrolled in the one or more clinical trial; and  
(g) the at least one trial **monitor** observing the one or more **clinical trial** to detect any deviations from the procedural guidelines.

13 The method of claim 12, farther...

...selecting the one or more trial participants to be enrolled in the one or more **clinical trial** , the at least one trial **monitor** observing the one or more **clinical trial** to detect any deviations from the procedural guidelines.

34

. The method of claim 14, wherein...

9/3,K/20 (Item 9 from file: 349)

DIALOG(R)File 349:PCT FULLTEXT

(c) 2003 WIPO/Univentio. All rts. reserv.

00904210

**SYSTEMS, METHODS AND COMPUTER PROGRAM PRODUCTS FOR GUIDING SELECTION OF A THERAPEUTIC TREATMENT REGIMEN BASED ON THE METHYLATION STATUS OF THE DNA**

**SYSTEMES, PROCEDES ET PROGICIELS D'ASSISTANCE DANS LE CHOIX D'UN SCHEMA POSOLOGIQUE TENANT COMPTE DE L'ETAT DE METHYLATION DE L'ADN**

Patent Applicant/Assignee:

EPIGENOMICS AG, Kastanienallee 24, 10435 Berlin, DE, DE (Residence), DE (Nationality), (For all designated states except: US)

Patent Applicant/Inventor:

BERLIN Kurt, Marienkaferweg 4, 14532 Stahnsdorf, DE, DE (Residence), DE (Nationality), (Designated only for: US)

OLEK Alexander, Schroderstrasse 13, 10115 Berlin, DE, DE (Residence), DE (Nationality), (Designated only for: US)

PIEPENBROCK Christian, Schwartzkopffstrasse 7 B, 10115 Berlin, DE, DE (Residence), DE (Nationality), (Designated only for: US)

Legal Representative:

SCHUBERT Klemens (agent), Joachimstrasse 9, 10119 Berlin, DE,  
Patent and Priority Information (Country, Number, Date):

Patent: WO 200237398 A2 20020510 (WO 0237398)  
Application: WO 2001EP12666 20011102 (PCT/WO EP0112666)  
Priority Application: US 2000705302 20001102

Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU  
CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP  
KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU  
SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW  
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR  
(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG  
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW  
(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Filing Language: English

Fulltext Word Count: 15810

Main International Patent Class: G06F-019/00

Fulltext Availability:

Detailed Description

Detailed Description

... flexible data driven architecture and custom reporting capabilities  
designed to support patient therapy management and **clinical drug trial**  
activities such as screening, patient **tracking** and support. It is  
anticipated that a system according to the present invention may be...

9/3,K/21 (Item 10 from file: 349)

DIALOG(R)File 349:PCT-FULLTEXT

(c) 2003 WIPO/Univentio. All rts. reserv.

00881365 \*\*Image available\*\*

REMOTE CONFIGURATION OF NETWORK NODE VIA CONTROLLER AREA NETWORK MESSAGES  
CONFIGURATION A DISTANCE DE NOEUD DE RESEAU PAR L'INTERMEDIAIRE DE MESSAGES  
DE RESEAU ELECTRONIQUE (CAN)

Patent Applicant/Assignee:

MICROCHIP TECHNOLOGY INCORPORATED, 2355 W. Chandler Boulevard, Chandler,  
AZ 85224-6199, US, US (Residence), US (Nationality)

Inventor(s):

STONEKING Rick, P.O. Box 4581, Warren, NJ 07059, US,  
NEGLEY Bruce, 2647 E. Bighorn Avenue, Phoenix, AZ 85048, US,  
FILICETTI Craig, 3816 North Jokake Drive, Scottsdale, AZ 85251, US,

Legal Representative:

PENNINGTON Edward A (agent), Swidler Berlin Shereff Friedman LLP, Suite  
300, 3000 K Street, N.W., Washington, DC 20007-5116, US,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200215517 A2-A3 20020221 (WO 0215517)  
Application: WO 2001US25588 20010816 (PCT/WO US0125588)  
Priority Application: US 2000639123 20000816

(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

Publication Language: English

Filing Language: English

Fulltext Word Count: 13481

International Patent Class: G06F-013/38

Fulltext Availability:

Detailed Description

Detailed Description

... Message-based networks are implemented in a wide variety of applications, including industrial automation, automotive/ track , medical equipment, test equipment and mobile machines. It will be appreciated that many of these networks are complex...

9/3,K/22 (Item 11 from file: 349)  
DIALOG(R)File 349:PCT FULLTEXT  
(c) 2003 WIPO/Univentio. All rts. reserv.

00872931 \*\*Image available\*\*  
**METHOD AND APPARATUS FOR THE PROCESSING OF REMOTELY COLLECTED ELECTRONIC INFORMATION CHARACTERIZING PROPERTIES OF BIOLOGICAL ENTITIES**  
**PROCEDE ET APPAREIL POUR LE TRAITEMENT DES INFORMATIONS ELECTRONIQUES COLLECTEES A DISTANCE CARACTERISANT LES PROPRIETES D'ENTITES BIOLOGIQUES**

Patent Applicant/Assignee:

LABNETICS INC, 10315 102nd Terrace, Sebastian, FL 32958, US, US  
(Residence), US (Nationality)

Inventor(s):

OTWORTH Michael J, Labnetics, Inc., 10315 102nd Terrace, Sebastian, FL 32958, US,  
SCOTT John S, Labnetics, Inc., 10315 102nd Terrace, Sebastian, FL 32958, US,  
BLACKWELL E Scott, Labnetics, Inc., 10315 102nd Terrace, Sebastian, FL 32958, US,  
MCMORRIS John A III, Labnetics, Inc., 10315 102nd Terrace, Sebastian, FL 32958, US,  
PACKARD Meagan J, Labnetics, Inc., 10315 102nd Terrace, Sebastian, FL 32958, US,  
COLE Andrew, Labnetics, Inc., 10315 102nd Terrace, Sebastian, FL 32958, US,  
MULLINS Gregory A, Labnetics, Inc., 10315 102nd Terrace, Sebastian, FL 32958, US,  
ACOSTA Galo F, Labnetics, Inc., 10315 102nd Terrace, Sebastian, FL 32958, US,  
FERRANS Richard H, Labnetics, Inc., 10315 102nd Terrace, Sebastian, FL 32958, US,

Legal Representative:

GARRETT Arthur S (et al) (agent), Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P., 1300 I Street, N.W., Washington, DC 20005-3315, US,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200207064 A2-A3 20020124 (WO 0207064)  
Application: WO 2001US22300 20010717 (PCT/WO US0122300)  
Priority Application: US 2000218583 20000717; US 2000218584 20000717; US 2000218585 20000717

Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW  
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR  
(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG  
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW  
(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Filing Language: English

Fulltext Word Count: 29888

Main International Patent Class: G06F-019/00

Fulltext Availability:

Detailed Description

Detailed Description

... laboratory director, or of the subject themselves, an authorization message may be received by the **clinical trial** manager or chemical **monitor** of the sponsor company from the subject related to the clinical trial. In this manner...

9/3,K/23 (Item 12 from file: 349)  
DIALOG(R)File 349:PCT FULLTEXT  
(c) 2003 WIPO/Univentio. All rts. reserv.

00859520 \*\*Image available\*\*

**CLINICAL TRIALS MANAGEMENT SYSTEM AND METHOD**  
**SYSTEME ET PROCEDE DE GESTION D'ESSAIS CLINIQUES**

Patent Applicant/Assignee:

FASTTRACK SYSTEMS INC, 1825 South Grant Street, Suite 310, San Mateo, CA 94402-2660, US, US (Residence), US (Nationality)

Inventor(s):

KAHN Michael G, 3980 Greenbriar Boulevard, Boulder, CO 80303, US,  
MISCHKE-REEDS Michael, 44 Brentwood Avenue, San Francisco, CA 94127, US,

Legal Representative:

WOLFELD Warren S (agent), Haynes & Beffel LLP, P.O. Box 366, Half Moon Bay, CA 94019, US,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200193178 A2 20011206 (WO 0193178)

Application: WO 2001US17488 20010531 (PCT/WO US0117488)

Priority Application: US 2000584936 20000531

Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU

CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP

KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD

SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW

(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Filing Language: English

Fulltext Word Count: 20253

Main International Patent Class: G06F-019/00

Fulltext Availability:

Detailed Description

Detailed Description

... of a particular protocol. The system. reports, this information to study sponsors, who can then **monitor** the progress of an overall **clinical trial** in near-real-time, and. to the central authority which can then generate performance metrics...

9/3,K/24 (Item 13 from file: 349)  
DIALOG(R)File 349:PCT FULLTEXT  
(c) 2003 WIPO/Univentio. All rts. reserv.

00859507 \*\*Image available\*\*

**CLINICAL TRIAL MANAGEMENT**  
**GESTION D'ESSAIS CLINIQUES**

Patent Applicant/Assignee:

ENMED INC, Suite 201, 35 Crosby Drive, Bedford, MA 01730, US, US  
(Residence), US (Nationality), (For all designated states except: US)

Patent Applicant/Inventor:

THANGARAJ Venkatesan, -, -- (Residence), -- (Nationality), (Designated only for: US)

REDDY Somashekar N, -, -- (Residence), -- (Nationality), (Designated only for: US)

Legal Representative:

DEVLIN Peter J (et al) (agent), Fish & Richardson P.C., 225 Franklin Street, Boston, MA 02110-2804, US,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200193160 A1 20011206 (WO 0193160)

Application: WO 2001US17214 20010525 (PCT/WO US0117214)

Priority Application: US 2000207616 20000526

Parent Application/Grant:

Related by Continuation to: US 2000207616 20000526 (CON)

Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU

CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP

KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD

SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW

(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Filing Language: English

Fulltext Word Count: 10669

Main International Patent Class: G06F-017/60

Fulltext Availability:

Detailed Description

Detailed Description

... user for authentication at different level of data access.

Audit trafis can be generated to **track** changes in the **clinical trial** data.

1 0 In another aspect, the invention provides methods and apparatus for operating a...of their products before they can be marketed in the U.S. The FDA-mandated **clinical trial** process requires **tracking**, date-stamping, and. coordination of hundreds of thousands of discrete data points from a nwnber...an audit trail (and is referred to as an "Audit Trail") and is used to **track** changes in data within the **clinical trial** management center 40.

21

14. Adverse Event Management: Adverse events are unforeseen medical emergencies that...

9/3,K/25 (Item 14 from file: 349)

DIALOG(R)File 349:PCT FULLTEXT

(c) 2003 WIPO/Univentio. All rts. reserv.

00839937 \*\*Image available\*\*

COMPUTER SYSTEM FOR PORTABLE DIGITAL DATA CAPTURE AND DATA DISTRIBUTION  
SYSTEME INFORMATIQUE DESTINE A LA CAPTURE PORTATIVE DE DONNEES NUMERIQUES  
ET A LA DISTRIBUTION DE DONNEES



Patent Applicant/Assignee:

NUMODA CORPORATION, The Curtis Center, 601 Walnut street, Philadelphia,  
PA 19106, US, US (Residence), US (Nationality)

Inventor(s):

BORIS Ann S, 6513 Shalkop Street, Philadelphia, PA 19128, US,  
ROTHBART Daniel, 99 Beals Street, Brookline, MA 02446, US,  
MURPHY Jeffrey, 2514 Flint Hill Road, Coopersburg, PA 18036, US,

Legal Representative:

JABLON Clark A (et al) (agent), Akin, Gump, Strauss, Hauer & Feld,  
L.L.P., One Commerce Square, Suite 2200, 2005 Market Street,  
Philadelphia, PA 19103-7086, US,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200173612 A1 20011004 (WO 0173612)

Application: WO 2001US9227 20010322 (PCT/WO US0109227)

Priority Application: US 2000192094 20000324; US 2000724541 20001127

Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ

DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ

LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG

SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW

(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Filing Language: English

Fulltext Word Count: 42298

Main International Patent Class: G06F-017/30

Fulltext Availability:

Detailed Description

Detailed Description

... distribution of data, whose accuracy is very important to an  
organization. For example, in a **clinical trial**, the Federal Drug  
Administration (FDA) **monitors** data very closely for correct or missing  
input. In order to reduce input error and...

9/3,K/26 (Item 15 from file: 349)

DIALOG(R)File 349:PCT FULLTEXT

(c) 2003 WIPO/Univentio. All rts. reserv.

00835853 \*\*Image available\*\*

**A SYSTEM AND METHOD FOR OBTAINING, PROCESSING AND EVALUATING PATIENT  
INFORMATION FOR DIAGNOSING DISEASE AND SELECTING TREATMENT  
SYSTEME ET PROCEDE POUR OBTENIR, TRAITER ET EVALUER DES INFORMATIONS  
RELATIVES AU PATIENT POUR DIAGNOSTIQUER UNE MALADIE ET SELECTIONNER UN  
TRAITEMENT**

Patent Applicant/Inventor:

ZAKIM David S, 323 Melrose Avenue, Mill Valey, CA 94941-3437, US, US  
(Residence), US (Nationality)

Legal Representative:

KENNARD Wayne M (et al) (agent), Hale and Dorr LLP, 60 State Street,  
Boston, MA 02109, US,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200169513 A2-A3 20010920 (WO 0169513)

Application: WO 2001US7339 20010307 (PCT/WO US0107339)

Priority Application: US 2000522792 20000310

Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ

DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ

LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG  
SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW  
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR  
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG  
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW  
(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Filing Language: English

Fulltext Word Count: 22512

Main International Patent Class: G06F-019/00

Fulltext Availability:

Detailed Description

Detailed Description

... vi) the reduction in the practice of "defensive medicine,"  
(vii) the planning and execution of **medical research** ,  
(viii) the **monitoring** of medical practice habits,  
(ix) patient education and treatment compliance,  
(x) preventive medicine. to reduce...

9/3,K/27 (Item 16 from file: 349)

DIALOG(R)File 349:PCT FULLTEXT

(c) 2003 WIPO/Univentio. All rts. reserv.

00835840 \*\*Image available\*\*

METHOD OF CONDUCTING SECURE CLINICAL TRIALS AND GUARANTEEING THE OCCURRENCE  
OF AN EVENT

PROCEDE PERMETTANT D'EFFECTUER DES ESSAIS CLINIQUES SANS DANGER ET DE  
GARANTIR L'OCCURRENCE D'UN EVENEMENT

Patent Applicant/Assignee:

MEDIDATA SOLUTIONS INC, 30 East 60th Street, Suite 1007, New York, NY  
10022, US, US (Residence), US (Nationality), (For all designated states  
except: US)

Patent Applicant/Inventor:

DE VRIES Glen M, 442 East 9th Street, Apt. 1A, New york NY 10009, US, US  
(Residence), US (Nationality), (Designated only for: US)  
IKEGUCHI Edward F, 36 Blossom Terrace, Larchmont, NY 10538, US, US  
(Residence), US (Nationality), (Designated only for: US)  
TE Alexis E, 111 Mill Spring Road, Manhasset, NY 11030, US, US  
(Residence), US (Nationality), (Designated only for: US)

Legal Representative:

DIPPERT William H (et al) (agent), Cowan, Liebowitz & Latman, P.C., 1133  
Avenue of the Americas, 35th Floor, New York, NY 10036, US,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200169490 A1 20010920 (WO 0169490)

Application: WO 2001US7533 20010309 (PCT/WO US0107533)

Priority Application: US 2000523551 20000310

Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ ,

DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ  
LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG  
SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW

(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Filing Language: English

Fulltext Word Count: 11642

Main International Patent Class: G06F-017/60

Fulltext Availability:

Detailed Description

Claims

#### Detailed Description

... Over time CROs compounded other value-added services to encompass a spectrum of services including **clinical trial** coordination, **monitoring** of data collection, identification of quality research trial investigators and sites, and centralized laboratory testing...paper document. This creates plenty of room for fraud and an obvious need for strict **monitoring**. As the **clinical research** field looks more to digital data capture and transmission, there is a greater need to...

...investigators in turn will select the trial participants or patients to be enrolled in the **clinical trial**. The **trial** monitors observe the conduct of the clinical trials to detect any deviations from the procedural guidelines...code field 270i comprising a plurality of random digits.

The current methods of administering a **clinical trial** involve **monitoring** the trial centers to assure research integrity. The basic role of the trial monitor is...submitted by the trial investigator corresponds to the source documentation, i.e., the patient's **medical** record. The **trial monitor** verifies whether the trial investigator has provided the ...will be able to have a real-time "bird's eye view" of the ongoing **clinical trial**. After **logging** in step 202, the trial administrator will be asked to authenticate him or herself as...

#### Claim

... selecting the one or more trial participants to be enrolled in the one or more **clinical trial**, the at least one trial **monitor** observing the one or more **clinical trial** to detect any deviations from the procedural guidelines.

t5

3 The method of claim 2...

9/3,K/28 (Item 17 from file: 349)

DIALOG(R)File 349:PCT FULLTEXT

(c) 2003 WIPO/Univentio. All rts. reserv.

00822303 \*\*Image available\*\*

**SYSTEMS AND METHODS FOR SELECTING AND RECRUITING INVESTIGATORS AND SUBJECTS FOR CLINICAL STUDIES**

**SYSTEMES ET PROCEDES PERMETTANT DE CHOISIR ET DE RECRUTER DES CHERCHEURS ET DES SUJETS POUR DES ETUDES CLINIQUES**

Patent Applicant/Assignee:

ACURIAN INC, 2 Walnut Grove Drive, Suite 375, Horsham, PA 19044, US, US  
(Residence), US (Nationality), (For all designated states except: US)

Patent Applicant/Inventor:

TUCKER Jennifer L, 257 Windsor Way, Doylestown, PA 19044, US, US  
(Residence), US (Nationality), (Designated only for: US)

HOLLWAY John F, 19 Harrison Drive, Newtown Square, PA 19073, US, US  
(Residence), US (Nationality), (Designated only for: US)

FLORIN Lawrence B, 1405 Ringneck Loop, Dresher, PA 19025, US, US  
(Residence), US (Nationality), (Designated only for: US)

HASPIEL Joseph B, 17 Arbor Road, St. Louis, MO 63132, US, US (Residence),  
US (Nationality), (Designated only for: US)

CONVERSE Lance, 39 High Gate Lane, Blue Bell, PA 19422, US, US  
(Residence), US (Nationality), (Designated only for: US)  
ROSENBERG Leonard, 735 Lippincott Avenue, Moorestown, NJ 08057, US, US  
(Residence), US (Nationality), (Designated only for: US)  
MICHELSON Leslie Dennis, 804 North Whittier Drive, Beverly Hills, CA  
90210, US, US (Residence), US (Nationality), (Designated only for: US)  
JAMES Steven P, 13292 Seagrove Street, San Diego, CA 92130, US, US  
(Residence), US (Nationality), (Designated only for: US)

Legal Representative:

MICALLEF Joseph A (et al) (agent), Arnold & Porter, 555 12th Street, NW,  
Washington, DC 20004, US,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200155942 A1 20010802 (WO 0155942)  
Application: WO 2001US2936 20010129 (PCT/WO US0102936)  
Priority Application: US 2000178634 20000128

Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ

DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ  
LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG  
SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW

(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Filing Language: English

Fulltext Word Count: 28021

Main International Patent Class: G06F-017/60

Fulltext Availability:

Detailed Description

Detailed Description

... invention.

Figs. 12-13 are exemplary web pages showing an extranet for creating,  
sending and **tracking** documents necessary to start a **clinical study**.

Figs. 14 is an exemplary electronic mail notification used for contacting  
a potential subject for...step 2132, information is stored in the  
inventive system database relating to prospective investigators for  
**clinical studies**, which includes regulatory agency **audits** that have  
been performed for each investigator. This information may include audits  
from the FDA...for example, the names and addresses of all of the  
investigators who conducted a particular **clinical study**. The FDA also  
performs **audits** on **clinical studies**, which can result in a Form  
483. Again, all non-confidential information from the 483...

9/3,K/29 (Item 18 from file: 349)

DIALOG(R)File 349:PCT FULLTEXT

(c) 2003 WIPO/Univentio. All rts. reserv.

00809404 \*\*Image available\*\*

TRACKING OF CLINICAL STUDY **SAMPLES, INFORMATION AND RESULTS**  
**LOCALISATION D'ECHANTILLONS D'ETUDES CLINIQUES, D'INFORMATIONS ET DE**  
**RESULTATS**

Patent Applicant/Assignee:

PPGx INC, 3900 Paramount Parkway, Morrisville, NC 27560, US, US  
(Residence), US (Nationality)

Inventor(s):

MARKIDAN Igor, 1109 Willowdale Dr., Cherry Hill, NJ 08003-2834, US,

OBEROI Himanshu, 49 N. Gate Park, Newton, MA 02465, US,  
MELNICK Jerald H, 6 Cameron Rd., Wayland, MA 01778, US,

Legal Representative:

CONNELL Gary J (et al) (agent), Sheridan Ross P.C., Suite 1200, 1560  
Broadway, Denver, CO 80203-5141, US,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200143038 A1 20010614 (WO 0143038)  
Application: WO 2000US33938 20001213 (PCT/WO US0033938)  
Priority Application: US 99170432 19991213

Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ

DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ  
LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG  
SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW

(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Filing Language: English

Fulltext Word Count: 3562

TRACKING OF CLINICAL STUDY SAMPLES, INFORMATION AND RESULTS

Main International Patent Class: G06F-017/60

Fulltext Availability:

Detailed Description

Claims

English Abstract

...and recording the results in the database. The present invention  
provides an automated system for **tracking clinical study** protocols,  
and allows access to information regarding a clinical study to be  
obtained from a...

Detailed Description

... for amending the  
claims and to be republished in the event of receipt of  
amendments.

TRACKING OF CLINICAL STUDY SAMPLES,  
INFORMATION AND RESULTS  
FIELD OF THE INVENTION  
The present invention relates to the tracking...

...information and makes difficult the retrieval of subject attributes and  
other information concerning individual samples. **Auditing** of samples  
from the **clinical study** and establishing a chain of custody  
concerning samples is also extremely difficult using paper based...

...hundreds and sometimes thousands of DNA samples can be collected from  
individuals participating in a **clinical study**.

Thus, accurate **tracking** of genotype information in an easily  
retrievable form during a clinical study is extremely complicated...  
...a traditional paper based system.

The system of the present invention provides for the automated **tracking**  
of **clinical study** protocols, and in particular of genotype  
information obtained from a **clinical study**.

The system integrates the **tracking** of individual samples using bar code

identifiers and computerized scanners, with checklists of procedures to ...

...of the present invention provides for the auditing of laboratory procedures used on samples from **clinical studies**. **Auditing** in this context includes, ...the present invention.

#### DESCRIPTION

In accordance with the present invention, a computer-implemented method for **tracking**: (1) **clinical study** samples through a clinical study; (2) the progress of a clinical study; and (3) recording the results obtained from procedures conducted during a **clinical study** is provided. Reference herein to "**tracking** samples of **clinical study**" and similar terms can refer to maintenance of the following information regarding samples in a...Changes made to the database also are tracked by the system, allowing complete and accurate **auditing** of samples from **clinical studies** and associated **clinical study** protocols. An **audit** report, according to one embodiment of the present invention, is illustrated in Fig. 10...foregoing description, a number of unique aspects of the disclosed method are illustrated. The method **tracks** information about **clinical study** protocols, the samples 5 collected in conjunction with those protocols, the procedures used to analyze...

#### Claim

I . A method for **tracking** samples of a **clinical study**, comprising: defining a first clinical study protocol comprising a plurality of procedures, wherein said procedures...

...determines the genotype of an individual. I 0 8. A computer implemented method for **tracking** samples of a **clinical study**, comprising:  
providing a computer;  
accessioning a plurality of samples, wherein identifying information is stored in...

9/3,K/30 (Item 19 from file: 349)

DIALOG(R)File 349:PCT FULLTEXT

(c) 2003 WIPO/Univentio. All rts. reserv.

00793262 \*\*Image available\*\*

METHOD AND SYSTEM FOR PROVIDING GENOTYPE CLINICAL INFORMATION OVER A COMPUTER NETWORK

PROCEDE ET SYSTEME PERMETTANT DE FOURNIR SUR UN RESEAU INFORMATIQUE DES RENSEIGNEMENTS CLINIQUES SUR LE GENOTYPE

Patent Applicant/Assignee:

ORCHID BIOSCIENCES INC, 303 College Road East, Princeton, NJ 08540, US,  
US (Residence), US (Nationality)

Inventor(s):

BOYCE-JACINO Michael, 2 Clark Court, Titusville, NJ 08560, US,  
GRANZOW Russell T, 237 Washington Crossing-Pennington Road, Titusville,  
NJ 08560, US,  
PFOST Dale R, 4 Rosedale Way, Pennington, NJ 08534, US,  
MARVIN Donald R, 60 Fair Acres Court, Princeton, NJ 08540, US,

Legal Representative:

KALOW David A (et al) (agent), Kalow & Springut LLP, 19th floor, 488  
Madison Avenue, New York, NY 10022, US,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200126029 A2-A3 20010412 (WO 0126029)

Application: WO 2000US40999 20000926 (PCT/WO US0040999)  
Priority Application: US 99411147 19991001  
Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ  
DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ  
LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG  
SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW  
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE  
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG  
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW  
(EA) AM AZ BY KG KZ MD RU TJ TM  
Publication Language: English  
Filing Language: English  
Fulltext Word Count: 7453

Main International Patent Class: G06F-019/00  
Fulltext Availability:  
Detailed Description

Detailed Description  
... Another example is described in U.S. Pat. No. 5,612,870 entitled  
"System For Tracking Secure Medical Test Cards", issued to Weiner.  
This patent is directed to a method and an apparatus for...

9/3,K/31 (Item 20 from file: 349)  
DIALOG(R) File 349:PCT FULLTEXT  
(c) 2003 WIPO/Univentio. All rts. reserv.

00772922 \*\*Image available\*\*  
**METHOD OF SEQUENCING CHRONIC DISEASE TESTING, REPORTING AND EVALUATION**  
**METHODES DE SEQUENCEMENT DES OPERATIONS DE TEST, DE COMMUNICATION ET**  
**D'EVALUATION DANS LE CADRE DE LA GESTION DE MALADIES CHRONIQUES**  
Patent Applicant/Inventor:  
SHEA Robert S, 5705 W. 129th Street, Overland Park, KS 66209, US, US  
(Residence), US (Nationality)  
MUSSATTO James J, 4424 W. 150th St., Leawood, KS 66224, US, US  
(Residence), US (Nationality)  
Legal Representative:  
STITT Richard P, 1000 Walnut St., Ste 1400, Kansas City, MO 64106, US  
Patent and Priority Information (Country, Number, Date):  
Patent: WO 200106429 A1 20010125 (WO 0106429)  
Application: WO 2000US18780 20000708 (PCT/WO US0018780)  
Priority Application: US 99353865 19990715  
Designated States: CA  
(EA) AM AZ BY KG KZ MD RU TJ TM  
Publication Language: English  
Filing Language: English  
Fulltext Word Count: 10808  
Main International Patent Class: G06F-017/60  
Fulltext Availability:  
Claims

Claim  
... comprising the steps of:  
determining a test parameters set for monitoring the patient,  
initializing a monitoring schedule sequence for said test set,  
selecting clinical testing materials appropriate to the patient disease  
state,  
transmitting said clinical testing materials to the...

9/3,K/32 (Item 21 from file: 349)  
DIALOG(R)File 349:PCT FULLTEXT  
(c) 2003 WIPO/Univentio. All rts. reserv.

00752878

**PHENOTYPE AND BIOLOGICAL MARKER IDENTIFICATION SYSTEM**  
**SYSTEME D'IDENTIFICATION DU PHENOTYPE ET DU MARQUEUR BIOLOGIQUE**

Patent Applicant/Assignee:

SURROMED INC, 1060 E. Meadow Circle, Palo Alto, CA 94303, US, US  
(Residence), US (Nationality)

Inventor(s):

RINGOLD Gordon, 12004 Adobe Creek Lodge Road, Los Altos Hills, CA 94022,  
US

DIETZ Louis J, 550 S. Shoreline Boulevard, Mountain View, CA 94041, US

KANTOR Aaron B, 37076 Arden Street, Newark, CA 94560, US

NATAN Michael J, 765 San Antonio Road, #56, Palo Alto, CA 94303, US

BRUNKE Karen J, 11 Somerset Court, Belmont, CA 94002, US

ALLISON Anthony, 2513 Hastings Drive, Belmont, CA 94002, US

Legal Representative:

SWANSON Barry J, Swanson & Bratschun, L.L.C., Suite 330, 1745 Shea Center  
Drive, Highlands Ranch, CO 80126, US

Patent and Priority Information (Country, Number, Date):

Patent: WO 200065472 A1 20001102 (WO 0065472)

Application: WO 2000US11296 20000426 (PCT/WO US0011296)

Priority Application: US 99131105 19990426; US 2000175075 20000107

Designated States: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK

DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR

LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ

TM TR TT TZ UA UG UZ VN YU ZA ZW .

(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

(AP) GH GM KE LS MW SD SL SZ TZ UG ZW

(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Filing Language: English

Fulltext Word Count: 31521

Main International Patent Class: G06F-017/00

Fulltext Availability:

Claims

Claim

... monitoring the response of said biological markers in said animal  
model.

66 A method for monitoring the results of a clinical study in  
humans with a given  
medical disease or condition comprising:  
evaluating biological markers in humans...

9/3,K/33 (Item 22 from file: 349)  
DIALOG(R)File 349:PCT FULLTEXT  
(c) 2003 WIPO/Univentio. All rts. reserv.

00561856 \*\*Image available\*\*

**INFORMATICS SYSTEM WEAVES**

**LIGNES ENTRECROISEES POUR SYSTEME INFORMATIQUE**

Patent Applicant/Assignee:

JOHNS HOPKINS SINGAPORE PTE LTD,



POSTON David,  
POSTON Timothy,  
RAGHAVAN Raghu,  
RAPPEL James Kolenchery,  
Inventor(s):  
POSTON David,  
POSTON Timothy,  
RAGHAVAN Raghu,  
RAPPEL James Kolenchery,  
Patent and Priority Information (Country, Number, Date):  
Patent: WO 200025229 A1 20000504 (WO 0025229)  
Application: WO 99SG103 19991022 (PCT/WO SG9900103)  
Priority Application: SG 983834 19981027  
Designated States: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK  
DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR  
LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ  
TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM  
AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL  
PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG  
Publication Language: English  
Fulltext Word Count: 8916

Main International Patent Class: **G06F-017/00**  
Fulltext Availability:  
Detailed Description

Detailed Description  
... 1400). If a case is classified as of research interest, parameters and  
conditions to be **monitored** are captured for **clinical research** .  
  
Weaves can be programmed to interact in different ways. Each weave is  
built Interactively from...

**9/3,K/34 (Item 23 from file: 349)**  
DIALOG(R)File 349:PCT FULLTEXT  
(c) 2003 WIPO/Univentio. All rts. reserv.

00542298 \*\*Image available\*\*  
**A METHOD FOR ANALYSIS OF BIOLOGICAL SYSTEMS**  
**PROCEDE D'ANALYSE DE SYSTEMES BIOLOGIQUES**  
Patent Applicant/Assignee:  
SMITH David,  
SMITH Roger,  
Inventor(s):  
SMITH David,  
SMITH Roger,  
Patent and Priority Information (Country, Number, Date):  
Patent: WO 200005671 A1 20000203 (WO 0005671)  
Application: WO 99AU597 19990723 (PCT/WO AU9900597)  
Priority Application: AU 986634 19980723  
Designated States: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE  
ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT  
LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT  
UA UG US UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD  
RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF  
CG CI CM GA GN GW ML MR NE SN TD TG  
Publication Language: English  
Fulltext Word Count: 7358  
Main International Patent Class: **G06F-019/00**  
International Patent Class: **G06F**

Fulltext Availability:  
Detailed Description

Detailed Description

... invention does have broader applications to  
biological systems in general.

Background of the Invention

In **medical research** and **monitoring** of patient  
behaviour it is currently the usual approach to "pool"  
data, i.e. to...

9/3,K/35 (Item 24 from file: 349)  
DIALOG(R)File 349:PCT FULLTEXT  
(c) 2003 WIPO/Univentio. All rts. reserv.

00532121 \*\*Image available\*\*

**CLINICAL TRIAL DATA MANAGEMENT SYSTEM AND METHOD**  
**SYSTEME ET PROCEDE DE GESTION DE DONNEES D'ESSAIS CLINIQUES**

Patent Applicant/Assignee:

PHASE FORWARD INC,

Inventor(s):

BLEICHER Paul A,  
STAMOS Nicholas,  
KLOFFT Jeffrey P,  
DALE Richard M,

Patent and Priority Information (Country, Number, Date):

Patent: WO 9963473 A2 19991209

Application: WO 99US12406 19990603 (PCT/WO US9912406)

Priority Application: US 9892441 19980605

Designated States: DE GB JP AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL  
PT SE

Publication Language: English

Fulltext Word Count: 14603

Main International Patent Class: G06F-019/00

Fulltext Availability:

Detailed Description

Detailed Description

... review roles to be  
performed at the Clinical Research Organization (CRO)  
and/or sponsor. The **Clinical Research Associate (CRA)**,  
**Clinical Data Manager**, **Medical Monitor**, and **Clinical**  
**Project Manager** review the data that is generated by the  
investigator sites for...

9/3,K/36 (Item 25 from file: 349)  
DIALOG(R)File 349:PCT FULLTEXT  
(c) 2003 WIPO/Univentio. All rts. reserv.

00520673

**SYSTEMS, METHODS AND COMPUTER PROGRAM PRODUCTS FOR GUIDING THE SELECTION OF**  
**THERAPEUTIC TREATMENT REGIMENS**

**SYSTEMES, PROCEDES ET PRODUITS DE PROGRAMMES INFORMATIQUES DESTINES A**  
**GUIDER LA SELECTION DE SCHEMAS THERAPEUTIQUESi( )**

Patent Applicant/Assignee:

TRIANGLE PHARMACEUTICALS INC,

BARRY David W,  
UNDERWOOD Carolyn S,  
McCREEDY Bruce J,  
HADDEEN David D,  
LUCAS Jason L,

Inventor(s):

BARRY David W,  
UNDERWOOD Carolyn S,  
McCREEDY Bruce J,  
HADDEEN David D,  
LUCAS Jason L,

Patent and Priority Information (Country, Number, Date):

Patent: WO 9952025 A2 19991014

Application: WO 99US7171 19990401 (PCT/WO US9907171)

Priority Application: US 9880629 19980403

Designated States: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK  
DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ  
LC LK LR LS LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK  
SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH GM KE LS MW SD SL SZ UG ZW AM  
AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL  
PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

Publication Language: English  
Fulltext Word Count: 11518

Main International Patent Class: G06F-017/60

International Patent Class: G06F-017/30

Fulltext Availability:

Detailed Description

Detailed Description

... data driven architecture and custom reporting  
capabilities designed to support patient therapy  
management and clinical drug trial activities such as  
screening, patient tracking and support. It is  
anticipated that a system according to the present  
invention may be...

9/3,K/37 (Item 26 from file: 349)

DIALOG(R)File 349:PCT FULLTEXT

(c) 2003 WIPO/Univentio. All rts. reserv.

00305859 \*\*Image available\*\*

COMPUTER SYSTEM FOR MANAGING PATIENT CARE

SYSTEME DE GESTION INFORMATIQUE DE SOINS MEDICAUX

Patent Applicant/Assignee:

MEDICAL DIMENSIONS INC,

Inventor(s):

CHRISTOPHER Kent L,  
BECKER Barron D,

Patent and Priority Information (Country, Number, Date):

Patent: WO 9524010 A1 19950908

Application: WO 95US2598 19950302 (PCT/WO US9502598)

Priority Application: US 94131 19940304

Designated States: AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU  
JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NL NO NZ PL PT RO RU SD  
SE SG SI SK TJ TT UA UG UZ VN KE MW SD SZ UG AT BE CH DE DK ES FR GB GR  
IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

Publication Language: English

Fulltext Word Count: 6341

Main International Patent Class: **G06F-015/00**

Fulltext Availability:

Detailed Description

Detailed Description

... used for  
billing purposes, for financial analysis of the physician's practice, and  
for statistical **studies tracking the medical** outcome of patients  
and  
treatment costs associated with various diagnoses.

The physician may also